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ABSTRACT 
 
Chronic complications are the leading cause of the mortality and morbidity in 
diabetic patients. Endothelial cell dysfunction plays an important role in the pathogenesis 
of chronic diabetic complications. Extracellular signal-regulated kinase 5 (ERK5) is 
essential for maintaining normal endothelial function and vascular integrity. This project 
investigated the role of ERK5 in the pathogenesis of diabetic retinopathy. Since increased 
endothelin-1 (ET-1), vascular endothelial growth factor (VEGF) and fibronectin (FN) are 
important features of diabetic complications, we examined the regulatory role of ERK5 
on ET-1, VEGF and FN production in diabetes. We also studied the mechanism of ERK5 
activation in this context.  
We examined expression of ERK5, ET-1, VEGF and FN in endothelial cells as 
well as in retinal tissues of diabetic rats. Results showed that ET-1, VEGF and FN 
expression were increased in endothelial cells treated with high levels of glucose as well 
as in retinal tissues of diabetic rats. These changes were associated with decreased ERK5 
activation. We used constitutively active MEK5 (CAMEK5) recombinant adenovirus to 
upregulate ERK5 signaling and showed that ET-1, VEGF and FN expression were 
significantly inhibited in endothelial cells in both basal and high glucose conditions. In 
contrast, ERK5 gene silencing stimulates ET-1, VEGF and FN expression. Dominant 
negative MEK5 (DNMEK5) transduction resulted in increase of glucose-induced ET-1, 
VEGF and FN synthesis. In vitro angiogenesis assay showed a markedly increased tube 
formation angiogenesis after ERK5 gene knockdown, indicating that elevated VEGF by 
siERK5 may contribute to the angiogenesis in diabetic retinopathy. Retinal tissue from 
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the diabetic animals also showed reduced ERK5. We also demonstrated that ERK5 is 
regulated by neurotrophins. 
 
Taken together, this study shows that ERK5 signaling may be involved in the 
pathogenesis of diabetic vasculopathy. ERK5 may lend itself as a potential target for the 
treatment of diabetic microangiopathy. 
 
KEYWORDS: Diabetic Complications, extracellular signal-regulated kinase 5, 
endothelin-1, vascular endothelial growth factor, fibronectin, transforming growth factor 
β1, nerve growth factor  
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CHAPTER 1: INTRODUCTION 
 
1.1 Diabetes  
 
Diabetes mellitus is characterized by high blood glucose levels, which produce 
the classical symptoms of polyuria (frequent urination), polydipsia (increased thirst) and 
polyphagia (increased hunger). Diabetes is usually diagnosed based on the fasting plasma 
glucose levels of ≥7.0 mmol/L (≥126 mg/dL), or with nonfasting glucose levels of >11.1 
mmol/L (>200 mg/dL) in the presence of classic symptoms (Vijan, 2010). There are two 
main types of diabetes: type 1 and type 2. Symptoms are obvious and develop rapidly in 
type 1 diabetes, while in type 2 diabetes symptoms may be subtle or absent and usually 
develop slowly. 
Type 1 diabetes is characterized by loss of the insulin-producing β cells of the 
pancreas leading to an absolute insulin deficiency. It accounts for approximately 10% of 
diabetes mellitus cases, mostly in children or in young adults. Wide variation in incidence 
of type 1 diabetes in children has been well characterized worldwide. Incidence varies 
from 0.1 per 100,000/year in China and Venezuela to 40.9 per 100,000/year in Finland 
(DIAMOND Project Group, 2006). The incidence of type 1 diabetes has increased 
rapidly over recent decades in young children (Patterson et al., 2009), which was thought 
to be associated with changes in environment or lifestyle leading to the alteration of 
humoral autoimmune response to islet antigens (Long et al., 2012). The presence of islet 
tissue-specific autoantibodies in sera from patients with type 1 diabetes is in supportive 
of such humoral response. However, there is overwhelming evidence, both in human and 
 2
in NOD mice, that T-cell-mediated autoimmunity play a major role in the disease 
development (Bluestone et al., 2010). Since pancreatic β cell loss and insulin deficency 
are the charactistic features of type 1 diabetes, insulin supplementation is required for the 
treatment. 
Type 2 diabetes makes up about 90% of cases of diabetes mellitus. It is 
characterized by insulin resistance with a relative insulin deficiency. In the early stage of 
type 2 diabetes, insulin production may be increased due to the peripheral resistance. An 
impairment of insulin secretion by pancreatic β cells may exist at later stage. 
Development of type 2 diabetes is a multifactorial process involving genetics factors and 
lifestyle (Ripsin et al., 2009). Most cases of type 2 diabetes involve many genes, each 
being a small contributor. Lifestyle factors, important in the development of type 2 
diabetes including: obesity (body mass index greater than thirty), lack of physical 
activity, poor diet and stress. Most persons with type 2 diabetes are overweight and 
obesity is thought to be the primary cause of type 2 diabetes in persons who are 
genetically predisposed to the disease. Lifestyle modification through diet and exercise 
can help  reduce the incidence of type 2 diabetes in patients with “prediabetes” (Norris et 
al., 2005). Interestingly, exercise significantly improved glycemic control, reduced 
visceral adipose tissue, and reduce plasma triglyceride levels in patients with type 2 
diabetes even without weight loss (Thomas et al., 2006). Therefore, lifestyle changes are 
considered first-line therapy for the management of type 2 diabetes. If such measures are 
inadequate, pharmacological interventions are initiated (Vijan, 2010;Rodbard et al., 
2007).  
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Both type 1 and type 2 diabetes can cause a number of complications affecting 
multiple organs. Acute complications include hypoglycemia, diabetic ketoacidosis and 
nonketotic hyperosmolar coma. Chronic complications typically develop after 10 to 20 
years, and include macroangiopathy and microangiopathy in selected organ systems. 
Chronic diabetic complications are the leading cause of mortality and morbidity in all 
types of diabetes (Laight et al., 1999;Panus et al., 2003). Macroangiopathy in diabetes is 
mainly due to an accelerated form of atherosclerosis, a pathological process initiated by 
injury of endothelial cells. Atherosclerosis affects all clinically important sites i.e., the 
coronary, the carotid and the peripheral arteries, thus increasing the risk of myocardial 
infarction, stroke, intermittent claudication and ischaemic gangrene (Guerci et al., 
2001a). Diabetes also causes microvascular complications. These include diabetic 
retinopathy and diabetic nephropathy (Klein, 1995). Diabetic nephropathy is a 
progressive kidney disease caused by microangiopathy in the kidney glomeruli. It is 
characterized by nephrotic syndrome and diffuse glomerulosclerosis (Tervaert et al., 
2010), and is a common cause of dialysis in Western countries. The present study is 
focused on diabetic retinopathy (detailed below). However, it should be noted that most 
of the pathological mechanisms may be similar in nephropathy and retinopathy. 
 
1.2 Diabetic retinopathy 
 
Diabetic retinopathy (DR) is a severe complication of diabetes, manifesting 
primarily as vascular structural and functional changes in the retina. DR may result in 
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vision loss and it is the most common cause of blindness in North America in the 25-74 
years age group (Aiello et al., 1998).  
 
DR has two phases, non-proliferative diabetic retinopathy (NPDR) and 
proliferative diabetic retinopathy (PDR) (Hudson, 1996;Khan and Chakrabarti, 2007). In 
NPDR phase, the vessels in the retina are weakened and leak, forming microaneurysms 
and retinal hemorrhages, which leads to decreased vision.  PDR is an advanced stage in 
which progressive microvascular abnormalities cause areas of the retina to become 
oxygen-deprived. New, but fragile, blood vessels develop on the surface of the retina or 
the optic disc as the organ system attempts to maintain adequate oxygen levels within the 
retina.  This is called neovascularization, a characteristic feature of PDR.  Unfortunately, 
these delicate vessels hemorrhage easily. In the later phases of the disease, continued 
abnormal vessel growth and scar tissue may cause tractional retinal detachment and 
blindness (Mohamed et al., 2007). Several growth factors and vasoactive factors are 
implicated in the development of PDR (Khan and Chakrabarti, 2003).  
 
Laser photocoagulation is the standard treatment for proliferative retinopathy. The 
Early Treatment Diabetic Retinopathy Study (ETDRS) results demonstrate that 
photocoagulation is effective in reducing the risk of visual loss and increases the chance 
of visual improvement (ETDRS, 1991). A vitrectomy is performed when there is vitreous 
hemorrhage, or retinal detachment with or without vitreous hemorrhage (Flynn, Jr. et al., 
1992). VEGF plays an important role in mediating intraocular neovascularization in 
patients with diabetic retinopathy (Aiello et al., 1994). Inhibition of ocular VEGF by 
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intravitreal injection of anti-VEGF drug has emerged as a promising treatment for PDR 
(Abdallah and Fawzi, 2009;Jardeleza and Miller, 2009). Recently, intravitreal anti-VEGF 
agents have been used in combination with standard therapeutic regimens in the treatment 
of proliferative diabetic retinopathy (Jardeleza and Miller, 2009;Montero et al., 2011). 
 
1.3 Mechanisms of vascular endothelial injury in diabetic complications 
 
Vascular endothelium is a major organ affected in chronic diabetic complications. 
It is viewed as both the target organ and potential mediator of diabetic vascular 
complications (Cosentino and Luscher, 1998;Laight et al., 1999).  
 
1.3.1 Normal endothelium 
 
The endothelium is the cell layer that lines blood vessels. It consists of a 
metabolically active monolayer of cells that perform a variety of roles in vascular 
homeostasis. Endothelium is a semipermeable barrier between the blood and the 
interstitium, facilitating the exchange of water and small molecules. The endothelium 
also participates in vasodilation. Furthermore, a healthy endothelium is able to inhibit 
platelet aggregation and adhesion, smooth muscle cell proliferation and leucocyte 
adhesion (Guerci et al., 2001b;Laight et al., 1999). The normal endothelial function is 
achieved through the regulation of a number of endothelium-derived signaling and 
adhesion molecules. Furchgott and Zawadzki (Furchgott and Zawadzki, 1980) discovered 
that the endothelium is essential for relaxation of the underlying vascular smooth muscle 
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by releasing nitric oxide (NO). Reactive oxygen species (ROS) are also produced by the 
endothelium in response to shear stress and endothelial agonists. Superoxide anion 
inactivates NO resulting in vasoconstriction in arteries (Mombouli and Vanhoutte, 1999). 
 
1.3.2 Evidence of endothelial dysfunction in diabetes 
 
Endothelial dysfunction has been observed to precede the onset of angiographic 
lesions (Cosentino and Luscher, 1998). Vasodilation of coronary arteries in response to 
pharmacological stimuli is reduced in diabetic rats (Sjogren and Edvinsson, 1988) and in 
humans (Nitenberg et al., 1998), indicating an impaired endothelium. Alterations in 
microcirculation consist of increased capillary pressure, blood flow and endothelial 
permeability, which are reversible at an early stage in diabetes. Irreversible structural 
modifications of the microvascular wall, such as thickening of the basement membrane 
due to the extracellular accumulation of proteins, take place at later stages. These 
alterations further affect microcirculation in diabetes by decreasing autoregulatory 
capacity and blood flow reserve (Cosentino and Luscher, 1998). 
 
1.3.3 Hyperglycemia is directly related to endothelial dysfunction 
 
Diabetes-associated conditions such as hypertension, dyslipidemia and insulin 
resistance are related to impaired endothelial function (Guerci et al., 2001a;Laight et al., 
1999;Panus et al., 2003). However, hyperglycemia is causally associated with endothelial 
dysfunction (Arosio et al., 1999;Laight et al., 1999). Evidences demonstrate impaired 
 7
endothelial vasodilator function during either acute or chronic hyperglycemia in both 
human (Akbari et al., 1998;Kim et al., 2003;Williams et al., 1998) and animal diabetes 
(Pieper et al., 1995;Tesfamariam and Cohen, 1992). In addition, hyperglycemia is known 
to increase endothelial permeability to macromolecules, delay cell replication, increase 
the secretion of sclerotic matrix proteins, increase adhesive properties for leukocytes and 
decrease the secretion of the pro-fibrinolytic agents, such as tissue plasminogen activator 
(tPA)(Laight et al., 1999). Furthermore, both the Diabetes Control and Complications 
Trial (DCCT) and the United Kingdom Prospective Diabetes Study (UKPDS) have 
demonstrated correlation of poor glycemic control with increased incidences of 
microvascular complications in patients with diabetes (DCCT, 1993;UKPDS, 1998). 
Clinical trials have also shown that macrovascular complications such as coronary artery 
disease (Kuusisto et al., 1994) and peripheral artery disease (Beks et al., 1995) is related 
to glycemic levels.  
 
1.3.4 Characteristic factors involved in diabetic retinopathy 
 
The biochemical mechanisms of hyperglycemia-induced endothelial dysfunction 
are under investigated at several laboratories. Potential mechanisms include 
hyperglycemia-mediated formation of oxygen-derived free radicals, advanced glycation 
end (AGE) products, protein kinase C(PKC) activation, and alteration of hexosamine 
pathway (Brownlee, 2005). Hyperglycemia also causes an alteration in vasoactive factors 
(Williams et al., 1998). It has been shown that hyperglycemia-induced endothelial 
dysfunction may result from decreased produc   tion of nitric oxide (NO), inactivation of 
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NO by oxygen-derived free radicals, and increased production of endothelium-derived 
vasoconstrictors (Cosentino and Luscher, 1998;Giugliano et al., 1997;Williams et al., 
1998). Three characteristic factors involved in early and late stages of diabetic 
retinopathy have been demonstrated including endothelin-1 (ET-1, involved in early and 
late stages), vascular endothelial growth factor (VEGF, involved in early and late stages) 
and fibronectin (FN, involved in late stage) (Chen et al., 2003b;Cukiernik et al., 
2004;Evans et al., 2000;Kaur et al., 2006;Roy et al., 1996;Takahashi et al., 1990). 
 
ET-1, produced by endothelial cells, is a potent vasoconstrictive peptide (Masaki, 
1989;Masaki, 1995;Yanagisawa et al., 1988). The activation of ET-1 also triggers the 
release of vasodilator (Guerci et al., 2001b;Mombouli and Vanhoutte, 1999). ET-1 is 
present in healthy subjects at low concentrations, and is involved in the maintenance of 
blood pressure (Masaki, 2000). Increased plasma ET-1 levels have been demonstrated in 
diabetics (Haak et al., 1992;Takahashi et al., 1990). In addition, circulating ET-1 levels 
correlate with a number of vascular complications in diabetic patients with clinical 
angiopathy (Laight et al., 1999). We have previously demonstrated that hyperglycemia-
induced augmented ET-1 production causes increased extracellular matrix (ECM) protein 
deposition (Figure 1.1) (Chen et al., 2002;Chen et al., 2003a;Evans et al., 2000). 
Furthermore, ET antagonist increases blood flow and prevents DR in diabetic animal 
models (Deng et al., 1999;Shaw et al., 2006;Takagi et al., 1996). 
 
FN is a multifunctional glycoprotein that plays important roles in various cellular 
events including cell adhesion, migration, differentiation and proliferation of fibroblasts 
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and ECs (Yamada and Olden, 1978;Yamada, 2000). Vascular basement membrane 
thickening is a histological hallmark of diabetic retinopathy (Ljubimov et al., 1996;Roy et 
al., 2010). We and others have shown that FN are overexpressed in retina vessels in 
animal and human diabetes (Evans et al., 2000;Roy et al., 1996), as well as in ECs 
cultured in high levels of glucose (Chen et al. 2003b; Chen et al. 2003a). It has been 
shown that TGFβ1 and ET-1 mediate FN accumulation in target organs, including retina 
in chronic diabetes (Evans et al., 2000;Khan et al., 2006;Sharma et al., 1996). FN may 
provide outside-in signaling for angiogenesis by increased production of important 
angiogenic factors like vascular endothelial growth factor (VEGF) (Astrof and Hynes, 
2009;Khan et al., 2005).  
 
VEGF is a key vasoactive factor implicated in the pathogenesis of DR. It is a 
major angiogenic factor in proliferative DR (Pe'er et al., 1995;Ray et al., 2004). VEGF 
also mediates the increased vascular permeability in the early stage of DR (Cukiernik et 
al., 2004;Hammes et al., 1998). Elevated VEGF mRNA and protein expression in the 
retina has been demonstrated in patients with DR (Boulton et al., 1998;Lutty et al., 
1996;Malecaze et al., 1994) and in the retina of streptozotocin-induced diabetic rats 
(Cukiernik et al., 2004;Hammes et al., 1998). Inhibition of VEGF has been shown to 
suppress retinal neovascularization in a murine model of ischemic retinopathy (Aiello et 
al., 1995). Consistent with in vivo observations, in vitro studies show that high glucose 
levels induce increased VEGF expression in ECs (Chen et al., 2000;Gao et al., 2008). 
VEGF has also been shown to interact with other vasoactive factors such as ET-1 in 
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mediating glucose-induced increased permeability in ECs (Chen et al., 2000;Cukiernik et 
al., 2004).  
 
1.4 Signaling pathways implicated in glucose-induced endothelial dysfunction 
 
Molecular mechanisms underlying the alteration of ET-1, VEGF, FN and 
endothelial dysfunction remain to be fully elucidated. Hyperglycemia-induced activation 
of protein kinase C (PKC) has been postulated to contribute to the vascular dysfunction in 
diabetes (Bursell et al., 1997;Ishii et al., 1996;Koya et al., 1997). Glucose-induced PKC 
activation increases mRNA expression of TGFβ1 and extracellular matrix components 
such as fibronectin and alpha1 (type IV) collagen in the glomeruli of diabetic rats (Koya 
et al., 1997). Phosphatidylinositol 3-kinases (PI3 kinase) is also considered to be involved 
in the endothelial dysfunction in diabetes (Panus et al., 2003). We and others have shown 
that both PKC and PI3 kinase pathways may converge on mitogen-activated protein 
kinase (MAPK) (Figure 1.1), which may represent a common signal transduction of 
glucose-induced endothelial dysfunction (Haneda et al., 1995;Haneda et al., 1997;Xin et 
al., 2004). Extracellular signal-regulated kinases 1 and 2 (ERK1/2) has been 
demonstrated to mediate high glucose-induced endothelial injury by increasing ET-1, FN 
and VEGF (Xin et al., 2004;Xin et al., 2005). ET-1 mediates downstream effect of 
glucose-induced ERK1/2 activation and stimulates FN accumulation in endothelial cells 
(Xin et al., 2004). FN is involved in angiogenesis by increased production of important 
angiogenic factors like vascular endothelial growth factor (VEGF) (Astrof and Hynes, 
2009;Khan et al., 2005). Moreover, glucose-induced FN expression was also associated 
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with activation of Akt/PKB, which is modulated by MAPK, PI3K and PKC (Xin et al., 
2005). Extracellular signal-regulated kinase 5 (ERK5) is the most recently identified 
member of MAPK (Lee et al., 1995;Zhou et al., 1995). However the exact role of ERK5 
in the pathogenesis of diabetic microangiopathy is unclear.  
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Figure 1.1: Molecular mechanism of high glucose-induced endothelial dysfunction 
A schematic outline of possible hyperglycemia-mediated alterations of signaling 
mechanisms converging on MAPK, leading to increased ET-1, FN and VEGF production 
in diabetic microangiopathy. PKC=protein kinase C, MAPK=mitogen-activated protein 
kinase. 
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1.5 Extracellular signal-regulated kinase 5 (ERK5) 
 
1.5.1 Introduction of ERK5 
 
MAPK plays a crucial role in regulating many cell processes including cell 
survival, proliferation and differentiation (Chang and Karin, 2001;Pearson et al., 
2001;Widmann et al., 1999). There are four distinct subfamilies of MAPKs: extracellular 
signal regulated kinase (ERK)1/2, ERK5, c-Jun NH2-terminal protein kinases (JNKs), 
and p38 MAPKs (Chang and Karin, 2001;Pearson et al., 2001;Widmann et al., 1999). 
ERK5, also termed big MAP kinase 1 (BMK1), is the most recently discovered member 
of the MAPK family. It was cloned by two independent groups in 1995 (Lee et al., 
1995;Zhou et al., 1995). ERK5 transcript is abundant in heart, placenta, lung, kidney and 
skeletal muscle (Lee et al., 1995;Zhou et al., 1995). ERK5 is highly expressed in 
endothelial cells (Yan et al., 1999). A recent study has shown that ERK5 is expressed in 
virtually all cells and is localized in nucleus as well as in the cytoplasm (Buschbeck and 
Ullrich, 2005). Studies in knockout mice have shown that the ERK5 pathway is critical 
for endothelial function and for the maintenance of vascular integrity (Hayashi et al., 
2001). 
 
1.5.2 Structure of ERK5 
 
Human ERK5 is a protein of 816 amino acids with a predicted molecular mass of 
98 kDa. ERK5 is encoded by MAPK7 gene, which is conserved in the majority of 
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mammals (sharing 80-98% homology). Rat ERK5 is a protein of 812 amino acids that 
share 97% homology with human ERK5.  SMA-5 is a homolog of ERK5 in C. elegans 
that is 60% similar to human ERK5 (Watanabe et al., 2005). Slt2p (Mpk1p) is an ERK5 
ortholog in Saccharomyces cerevisiae (Truman et al., 2006).  
 
ERK5 is more than twice the size of the other MAPKs due to its unique C-
terminal. The N-terminal of conserved MAPK catalytic domain share greater than 50% 
homology with ERK1/2, which contains the Thr–Glu–Tyr (TEY) dual phosphorylation 
motif in the activation loop (Figure 1.2) (Zhou et al., 1995). The C-terminal of ERK5 
contains a nuclear localization signal (NLS) and two proline-rich regions (Figure 1.2). 
The NLS is crucial for the nuclear localization of ERK5 upon stimulation. The proline-
rich regions may serve as binding sites for Src homology 3 (SH3) domain containing 
proteins (Buschbeck and Ullrich, 2005;Yan et al., 2001;Zhou et al., 1995).  
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Figure 1.2: Structure and activation of ERK5.  
ERK5 is a protein of 816 amino acids. The N-terminal contains the TEY dual 
phosphorylation motif in the activation loop. The C-terminal of ERK5 contains a nuclear 
localization signal (NLS) and two proline-rich regions. ERK5 has two mechanisms for 
signaling; kinase activation and transcriptional activation of targets. Kinase activation is 
similar to other members of MAPKs. Transcriptional activation is unique for ERK5. 
ERK5 is activated by dual phosphorylation at Thr218/Tyr220 by the upstream kinase 
MEK5. Active ERK5 is able to undergo autophosphorylation on the C-terminal, leading 
to an enhancement of ERK5 transcriptional activity. Diagram is modified from Drew et 
al. 2012. 
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1.5.3 Mechanisms of ERK5 activation 
 
ERK5 has two mechanisms for signaling; kinase activation and transcriptional 
activation of targets (Figure 1.2) (Nishimoto and Nishida, 2006;Roberts et al., 2009). 
Kinase activation is similar to other members of MAPKs, However, the transcriptional 
activation is unique for ERK5.  These modes of activation are discussed below. 
 
1.5.3.1 Kinase activation of ERK5 
 
MAPK signalling cascades consists of three sequentially activated kinases: a 
MAP kinase kinase kinase (MEKK); a MAP kinase kinase (MEK); and a MAP kinase 
(MAPK). These kinase modules relay signals from extracellular agonists to cellular 
targets. The signaling modules in the ERK5 pathway are composed of MEKK2/MEKK3, 
MEK5, and ERK5 (Figure 1.3) (Chao et al., 1999;Lee et al., 1995;Sun et al., 2001;Zhou 
et al., 1995). MEKK2/MEKK3 phosphorylate MEK5 on Ser311 and Thr315, resulting in 
an increase in MEK5 activity (Chao et al., 1999). The MEK5 cDNA encodes a 444-
amino acid protein, which displays 40% identity to other MEKs (English et al., 
1995;Zhou et al., 1995). MEK5 has multiple splice variants including 50 kDa MEK5α 
and 40 kDa MEK5β isoforms (English et al., 1995;Zhou et al., 1995). MEK5β is 
ubiquitously distributed, MEK5α is expressed most highly in liver and brain (English et 
al., 1995). MEK5α is also found in endothelial cells (Hayashi et al., 2005). The N-
terminal of MEK5α contains a phox and Bem1p (PB1) domain, which mediates the 
binding interaction of MEK5α with MEKK2/3 (Nakamura and Johnson, 2003). Inhibiting 
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the PB1-dependent formation of the MEKK/MEK5 complex has been shown to inhibit 
activation of MEK5α (Nakamura and Johnson, 2003;Seyfried et al., 2005). MEK5α is a 
stronger activator of ERK5, compared to MEK5β, since MEK5β lacks an extended N-
terminus containing PB1 domain (Seyfried et al., 2005). Similarly, Cameron et al’ study 
has shown that MEK5α, but not MEK5β, activates ERK5 (Cameron et al., 2004). 
Mutation of dual phosphorylation MEK5α sites (Ser311Asp and Thr315Asp; MEK5α 
(S311D/T315D)) activated ERK5, but similar mutation of MEK5β was unable to cause 
ERK5 kinase activation or nuclear translocation (Cameron et al., 2004). It was also 
shown that MEK5β is possibly a naturally occurring dominant-negative splice variant 
protein that prevents excessive BMK1 activation and aberrant cell growth (Cameron et 
al., 2004). 
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Figure 1.3: Activators of ERK5 pathway. 
The signaling modules in the ERK5 pathway are composed of MEKK2/MEKK3, MEK5, 
and ERK5. ERK5 is activated by a variety of stimuli. It can be activated by serum and a 
range of growth factors including EGF, FGF2, VEGF and NGF. It can also be activated 
by cytokines such as LIF and IL-6. Additionally, ERK5 is activated by a range of stress 
stimuli such as osmotic stress, fluid shear stress, oxidative stress, hypoxia and ischemia.  
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ERK5 is activated by dual phosphorylation at Thr218/Tyr220 by the upstream 
kinase MEK5 (English et al., 1995;Lee et al., 1995;Zhou et al., 1995). MEK5 
preferentially phosphorylates ERK5 on Thr218, which might induce a conformational 
change and subsequent phosphorylation of Tyr220 (Mody et al., 2003). Active ERK5 is 
able to undergo autophosphorylation on the C-terminal at a number of residues including 
Thr28, Ser421, Ser433, Ser496, Ser731 and Thr733, leading to an enhancement of ERK5 
transcriptional activity as described above. Activated ERK5 also phosphorylates MEK5 
at residues 129, 137, 142 and 149 which are located in the region that is thought to 
interact with ERK5 (Mody et al., 2003). PKCζ, an atypical protein kinase C, has been 
reported to interact with MEK5 through their respective PB1 domains in EGF-induced 
activation of ERK5 (Diaz-Meco and Moscat, 2001;Sumimoto et al., 2007). Interestingly, 
a recent study demonstrated that PKCζ is directly associated with ERK5. PKCζ mediates 
inhibitory phosphorylation of ERK5 by binding and phosphorylating serine 486, thus 
suppressing ERK5 function in TNFα-mediated inflammatory process (Nigro et al., 2010).  
 
1.5.3.2 Transcriptional activation of ERK5  
 
The C-terminal region of ERK5 contains a transcriptional activation domain, 
which is required for maximal transcriptional activity of target molecules (Buschbeck and 
Ullrich, 2005;Kasler et al., 2000;Terasawa et al., 2003). Activated ERK5 phosphorylates 
itself at the C-terminal at a number of residues (Mody et al., 2003) and 
autophosphorylation of C-terminal region of ERK5 leads to enhanced transcriptional 
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activity (Kasler et al., 2000;Morimoto et al., 2007). Once stimulated, phosphorylation of 
ERK5 results in the activation of the kinase activity. ERK5 phosphorylates both 
downstream target molecules and its carboxy-terminal region (Figure 1.2). Thus, 
autophosphorylation of the C-terminal leads to a further increase in the transcription 
activity of target molecules (Morimoto et al., 2007). In addition, Morimoto et al. showed 
that the activated kinase activity of ERK5 is required for the C-terminal mediated 
transcriptional activation of downstream targets. Mutation of phosphorylatable threonine 
and serine residues to unphosphorylatable alanines significantly reduces the 
transcriptional activation effect of ERK5 (Morimoto et al., 2007).  Interestingly, C-
terminal also regulates the kinase activation of N-terminal. Deletion of C-terminal results 
in dramatic increase of kinase activation of N-terminal (Buschbeck and Ullrich, 2005). 
 
 
1.5.4 Regulators of ERK5 signaling 
 
Similar to other MAPKs, ERK5 is activated by a variety of stimuli (Figure 1.3). 
Studies have revealed that it is activated by serum (Kato et al., 1997), a range of growth 
factors including epidermal growth factor (EGF) (Kato et al., 1998), fibroblast growth 
factor-2 (FGF-2) (Kesavan et al., 2004), VEGF (Hayashi et al., 2001), and by cytokines 
such as leukaemia inhibitory factor (LIF) (Nicol et al., 2001) and interleukin 6 (IL-6) 
(Carvajal-Vergara et al., 2005). Additionally, neurotrophins, such as brain-derived 
neurotrophic factor (BDNF), nerve growth factor (NGF), use the ERK5 pathway to 
mediate neuronal cell survival (Watson et al., 2001). ERK5 is also activated by a range of 
 24
stress stimuli such as osmotic and oxidative stresses (Abe et al., 1996), fluid shear stress 
(Yan et al., 1999), hypoxia (Sohn et al., 2002) and ischemia (Takeishi et al., 1999). G-
proteins are involved in the activation of ERK5 by growth factors (Obara and Nakahata, 
2010). In addition, studies have shown that PKCζ mediates ERK5 activation by G 
protein-coupled receptors (GPCR) (Diaz-Meco and Moscat, 2001;Garcia-Hoz et al., 
2010;Nigro et al., 2010). It has also been reported that G protein acts as an adaptor 
protein in PKCζ-mediated ERK5 activation by GPCR (Garcia-Hoz et al., 2010).  
 
 
1.5.5 Substrates of ERK5 signaling 
 
A number of molecules have been identified as substrates of the ERK5 pathway. 
The transcription factors of the myocyte enhancer factor 2 (MEF2) family are best-
characterized substrates of ERK5 (Kato et al., 1997;Kato et al., 2000;Yang et al., 1998). 
MEF2 is a four-membered family of transcription factors including MEF2A, MEF2B, 
MEF2C and MEF2D. ERK5 phosphorates and activates MEF2A, MEF2C and MEF2D, 
but not MEF2B (Kato et al., 1997;Kato et al., 2000). The C-terminal tail of ERK5 
contains a MEF2-interacting region and a transcriptional activation domain essential for 
coactivation of MEF2 (Kasler et al., 2000). Activation of the MEF2 by the ERK5 is 
essential for endothelial cell survival and proliferation (Kato et al., 1997;Olson, 2004). In 
addition, Krueppel-like factor 2 (KLF2) is identified as an ERK5 responsive gene and 
ERK5 drives KLF2 transcription by activating MEF2 (Sohn et al., 2005). KLF2 plays an 
important role in regulating inflammation and angiogenesis and maintaining vascular 
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quiescence (Boon and Horrevoets, 2009;Dekker et al., 2006;Senbanerjee et al., 
2004;Sohn et al., 2005;Suzuki et al., 2005).  
 
 Ets-domain transcription factor (Sap1a) and serum- and glucocorticoid-inducible 
kinase (SGK) have also been identified as the downstream targets of ERK5 and plays an 
important role in cell proliferation induced by growth factors (Hayashi et al., 
2001;Kamakura et al., 1999). Moreover, the ERK5 signaling pathway stimulates the 
transcriptional activity of c-Fos and Fra-1 (fos-related antigen 1), and members of the 
AP-1 (activator protein 1) family (Terasawa et al., 2003). Other downstream substrates of 
ERK5 include Cx43 (connexin 43; a gap junction protein) (Cameron et al., 2003), BAD 
(a pro-apoptotic member of Bcl-2 family) (Pi et al., 2004), C-Myc proto-oncogene 
(English et al., 1998) and CREB (cAMP response element binding protein) (Watson et 
al., 2001). 
 
 
1.6 Potential role of ERK5 in endothelial dysfunction in diabetes 
 
1.6.1   Role of ERK5 in endothelial cell 
 
ERK5 is highly expressed in the endothelial cells and is essential for maintaining 
endothelial function and blood vessel integrity (Hayashi et al., 2001). ERK5-deletion is 
lethal. These mice die around embryonic day 10 (E10) due to cardiovascular defects 
(Regan et al., 2002;Sohn et al., 2002;Yan et al., 2003). Similar phenotypic abnormalities 
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are observed in the mekk3−/−, mek5−/− and mef2−/− embryos, suggesting that the 
MEKK3/MEK5/ERK5/MEF2 cascade is critical to the cardiovascular development (Lin 
et al., 1997;Wang et al., 2005;Yang et al., 2000). Additional studies by targeted deletion 
of ERK5 gene in mice have shown that ERK5 is essential in endothelial cell physiology, 
but not in the cardiac development (Hayashi et al., 2004). Endothelial cells specific 
ERK5 ablation generates the same heart defects as those observed in global ERK5 
knockout mutants, whereas cardiomyocyte specific ERK5 deletion mice are normal 
(Hayashi et al., 2004). These results indicate that ERK5 is critical for endothelial cell 
function and that the abnormal heart development in the mice lacking ERK5 is a 
consequence of endothelial cell dysfunction (Hayashi et al., 2004). Additionally, ERK5 is 
required to maintain vascular integrity in adult mice. Adult mice display hemorrhages in 
multiple organs and die within 2–4 weeks after deletion of ERK5 (Hayashi et al., 2004). 
In addition to these in vivo studies, ERK5 has been shown to be essential for endothelial 
cells survival in vitro (Hayashi et al., 2004;Pi et al., 2004). Deletion of ERK5 induces 
profound endothelial cell apoptosis. Introduction of exogenous ERK5 can prevent 
endothelial cells from cell death (Hayashi et al., 2004). Similarly, activation of ERK5 by 
constitutively active MEK5 (CAMEK5) significantly improved cell viability and 
decreased apoptosis induced by growth factor deprivation (Pi et al., 2004). In addition, 
CAMEK5 inhibited growth factor deprivation-induced apoptosis, whereas dominant 
negative ERK5 (DNERK5) stimulated apoptosis in endothelial cells (Pi et al., 2004). 
ERK5 pathway also mediates the shear stress-induced antiapoptotic effect in endothelial 
cells (Pi et al., 2004;Yan et al., 1999). Inhibition of ERK5 activity by overexpression of 
dominant negative ERK5 reduces endothelial-protective effect of shear stress (Pi et al., 
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2004). Analysis of antiapoptotic mechanisms of ERK5 showed that MEF2C, a direct 
substrate of ERK5 mediates endothelial cell survival signal (Hayashi et al., 2004). 
Studies on the role of ERK5 in diabetic macrovascular and microvascular diseased are 
summarized as follows (Figure 1.4). 
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Figure 1.4: Potential role of ERK5 in chronic diabetic complications. 
A diagrammatic outline of potential role of ERK5 in chronic diabetic complications. 
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1.6.2 Role of ERK5 in diabetic macrovascular diseases 
 
It has been shown that ERK5 is involved in diabetic macroangiopathy. 
Macroangiopathy in diabetes is mainly due to an accelerated form of atherosclerosis 
(Guerci et al., 2001a). Steady and laminar blood flow is known to be atheroprotective, 
and has been shown to be a strong activator of ERK5 (Yan et al., 1999). Also, ERK5 
activation has been demonstrated to be atheroprotective (Pi et al., 2004). Inhibition of 
ERK5 activity by dominant negative ERK5 (DNERK5) reduces the endothelial cell-
protective effect of shear stress (Pi et al., 2004), indicating that the ERK5 mediates the 
shear stress-induced antiapoptotic effect in endothelial cells. This may be mediated by 
phosphorylation of BAD (Pi et al., 2004). Sohn et al. revealed that KLF2 mediates 
endothelial-protective effect of ERK5 (Sohn et al., 2005). KLF2 is a critical 
transcriptional regulator for vasoprotective effect of shear stress (Boon and Horrevoets, 
2009;Parmar et al., 2006). In addition, laminar flow-induced ERK5 activation has been 
shown to confer an atheroprotective effect by inducing peroxisome proliferator-activated 
receptor gamma (PPARγ) (Akaike et al., 2004) and inhibiting tumor necrosis factor α 
(TNFα) mediated adhesion molecule expression in endothelial cells (Li et al., 2008). 
However, protective effect of ERK5 is inhibited by SUMOylation in diabetes (Woo et al., 
2008). Small ubiquitin-like modifier (SUMO) covalently attaches to certain residues of 
specific target proteins and negatively regulates transcription factors (Verger et al., 
2003;Wang and Tournier, 2006). Increased ERK5 SUMOylation was observed in the 
aortas from diabetic mice as well as endothelial cells treated with H2O2 and AGE (Woo et 
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al., 2008). ROS and advanced AGE are two well-known mediators of diabetic vascular 
disease. H2O2 and AGE induce ERK5 SUMOylation and inhibit shear stress-mediated 
ERK5’s transcription activity. Subsequently decreased KLF2 and eNOS expression lead 
to endothelial dysfunction and accelerate atherosclerosis in diabetes (Woo et al., 2008).  
 
1.6.3 Role of ERK5 in diabetic microangiopathy  
 
A number of studies have been performed to study the role of ERK5 on diabetic 
nephropathy. Mesangial expansion is an important structural change in diabetic 
nephropathy (Dalla et al., 2001). Glucose activates ERK5 and promotes rat mesangial 
cells proliferation (Suzaki et al., 2004). ERK5 also mediates human mesangial cell 
activation by glucose as well as other agonists causing mesangial cell proliferation and 
extracellular matrix accumulation (Dorado et al., 2008). Moreover, Suzaki et al has 
demonstrated that ERK5 is activated in glomerular mesangial cells of diabetic rat and 
concluded that ERK5-mediated mesangial cell growth may be involved in the 
pathogenesis of diabetic nephropathy (Suzaki et al., 2004). Similarly, ERK5 increases 
mesangial cell viability and collagen matrix accumulation in glomerulonephritis 
(Urushihara et al., 2010). Furthermore, it has been shown that SGK1 is upregulated in 
diabetic nephropathy and mediates extracellular matrix deposition in human mesangial 
cells exposed to high glucose (Feng et al., 2005). SGK1 is a downstream target of ERK5 
signaling (Hayashi et al., 2001), therefore, it is possible that ERK5 is involved in diabetic 
nephropathy by activating SGK1. These results show that ERK5 activation contributes to 
the pathogenesis of diabetic nephropathy.  
 32
 
However, a recent report showed a different effect of ERK5 on renal disease. 
ERK5 mediates renal protection against ischemia reperfusion injury (Kawakami et al., 
2012). It was shown that there is a kidney-specific ERK5 with a smaller molecular mass, 
which may be partially functional. Overexpression of full length ERK5 in the mouse 
kidneys provided protection against renal ischemia reperfusion injury (Kawakami et al., 
2012). It is possible that ERK5 overexpression may also protect patients with diabetes 
from diabetic nephropathy.  
 
Although ERK5 is potentially important in diabetic microangiopathy, the in-depth 
investigation of glucose-induced ERK5 signaling has not been carried out. Furthermore 
no studies have been performed with respect to diabetic retinopathy, a characteristic 
microangiopathy in chronic diabetes. 
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1.7 Rationale, hypothesis and specific aims  
 
As outlined above, ERK5 plays an important role in maintaining normal 
endothelial function. Endothelial dysfunction is a key mechanism in the pathogenesis of 
chronic diabetic complications, which leads to increase of endothelium derived factors 
such as ET-1, VEGF and FN. It is possible that alteration of ERK5 may regulate these 
endothelium derived factors.  
 
Therefore, we hypothesize that alteration of ERK5 signaling plays a 
pathogenesis role in diabetic vascular complication, specifically in the development 
of diabetic retinopathy via increasing vasoactive factors and extracellular matrix 
proteins. 
 
Following are the specific aims of the study: 
i. To study the role of ERK5 signaling in ET-1 expression in endothelial cells and in 
the retina of diabetic animals. 
ii. To study the role of ERK5 signaling in glucose-induced VEGF expression and 
angiogenesis in endothelial cells.  
iii. To study the role of ERK5 signaling in glucose-induced FN production and to 
investigate the regulators of ERK5 signaling. 
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CHAPTER 2: Glucose-induced endothelin-1 expression is regulated by ERK5 in the 
endothelial cells and retina of diabetic rats 
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2.1 INTRODUCTION 
 
 
Diabetes mellitus is a major cause of  micro- and macroangiopathy (Guerci et al., 
2001). Chronic complications, involving the blood vessels, are the leading causes of 
mortality and morbidity in patients with diabetes (Laight et al., 1999;Panus et al., 2003). 
Endothelium is a major player in diabetic vascular diseases which may function both as a 
target organ and as a mediator  (Cosentino and Luscher, 1998;Laight et al., 1999). 
Endothelial dysfunction has been demonstrated to precede the onset of angiographic 
lesions in diabetes (Cosentino and Luscher, 1998). Hyperglycemia is directly related to 
endothelial dysfunction (Arosio et al., 1999;Laight et al., 1999). Large-scale clinical trials 
have demonstrated an increased incidence of microvascular complications (, 1993), 
coronary artery disease (Kuusisto et al., 1994) and peripheral artery disease (Beks et al., 
1995) in patients with poorly controlled diabetes. Increased production of endothelins 
(ET) has been demonstrated in several organs in chronic diabetic complications (Khan 
and Chakrabarti, 2003). Endothelin-1 (ET-1) is a potent vasoconstrictive peptide which 
shows a widespread tissue distribution and a large number of actions (Masaki, 
1989;Masaki, 1995;Yanagisawa et al., 1988). ET-1 is present in healthy subjects at low 
concentration, involved in maintenance of blood pressure (Masaki, 2000). Increased 
plasma ET-1 levels have been demonstrated in diabetics (Takahashi et al., 1990;Haak et 
al., 1992;Takahashi et al., 1990). In addition, circulating ET-1 levels correlates with the 
incidence of vascular complications in diabetics (Laight et al., 1999). Previous studies in 
our lab have demonstrated important role of glucose-induced upregulation of ET-1 in 
augmented extracellular matrix (ECM) protein production and vascular dysfunction in 
diabetes (Chen et al., 2002;Chen et al., 2003a;Evans et al., 2000;Chen et al., 2003b). We 
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have also demonstrated that glucose-induced, ET-dependent upregulation of ECM 
proteins are mediated via extracellular signal regulated kinase (ERK; also known as 
mitogen-activated protein kinase (MAPK)) (Xin et al., 2004). MAPK activation have 
been implicated in various lesions in chronic diabetic complications by other 
investigators (Haneda et al., 1997;Xin et al., 2004;Liu et al., 2000).  
 
ERK5, also known as big mitogen-activated protein kinase 1 (BMK1), was 
identified as a member of the MAPK family in 1995 (Lee et al., 1995;Zhou et al., 1995). 
ERK5 is a protein of 816 amino acid residues with a large COOH terminal and a unique 
loop-12 sequence. ERK5 is activated by MAPK/ERK kinase 5 (MEK5). ERK5 
transcripts are abundant in heart, placenta, lung, kidney and skeletal muscle (Lee et al., 
1995;Zhou et al., 1995). ERK5 is highly expressed in endothelial cells (Yan et al., 1999). 
Studies in knock-out mice have shown that the ERK5 pathway is critical for endothelial 
function and for maintaining blood vessel integrity (Hayashi et al., 2004). Shear stress 
stimulates ERK5 activation in ECs (Pi et al., 2004;Yan et al., 1999). Studies also have 
shown that high glucose levels induce ERK5 activation in ECs (Liu et al., 2000). In 
addition, it has been reported that ERK5 is activated in glomeruli of diabetic rats and in 
mesangial cells by high glucose levels (Suzaki et al., 2004). ERK5 is different from other 
MAPK as it has a transcriptional activation domain, mediating protein-protein interaction 
with transcription factors such as Myocyte Enhancing Factor 2 (MEF2) and Kruppel-like 
factor 2 (KLF2). BMK1-MEF2 signaling is essential for endothelial survival and 
proliferation (Olson, 2004). ERK5 activates MEF2 at the KLF2 promoter site. KLF2 
plays a leading role in the regulation of endothelial cell gene expression  and has been 
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shown to negatively regulate ET-1 expression (Boon et al., 2007;Dekker et al., 
2006;Parmar et al., 2006). Hence, we investigated whether ERK5 activation regulates 
glucose-induced ET-1 expression and if such regulation is mediated through MEF2/KLF2 
signaling in the ECs. We further expanded the study to investigate whether a similar 
mechanism is of importance in the retina, a target organ of chronic diabetic complications. 
 
 
2.2 MATEERIALS AND METHODS 
 
2.2.1 Cell culture 
 
Human umbilical vein endothelial cells (HUVECs) and dermal-derived normal 
human microvascular endothelial cells (HMVECs) were obtained from Lonza 
Walkersville, Inc. (Walkersville, MD). The culture conditions have previously been 
described (Chen et al., 2004). Briefly, HUVECs were cultured in EC basal medium 
(EBM, Lonza) supplemented with 10 µg/L human recombinant epidermal growth factor 
(hEGF), 1.0 mg/L hydrocortisone, 50 mg/L gentamycin, 12 mg/L bovine brain extract 
(BBE), and 8% fetal bovine serum (FBS). HMECs were grown in EC basal medium 2 
(EBM-2, Lonza, Walkersville, MD) containing hEGF, 1‰; Hydrocortisone, 0.4‰; 
gentamycin, 1‰; FBS, 10%; VEGF, 1‰; human fibroblast growth factor - basic (hFGF-
B), 4‰; long R3 insulin-like growth factor (R3-IGF-1), 1‰; ascorbic acid, 1‰. In both 
EBM and EBM2, the glucose concentration was 5 mmol/L. Both cell types were grown 
in 25 cm2 tissue culture flasks and maintained in a humidified atmosphere containing 5% 
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CO2 at 37ºC. Cells at 80% confluence were growth arrested by incubation in serum-free 
medium overnight prior to treatment with glucose (25mM).  
 
2.2.2 Gain and loss of function studies 
 
For gain of function study, constitutively active human recombinant MEK5 
(CAMEK5) adenovirus (Cell Biolabs, San Diego, CA) was used to activate ERK5. Cells 
were seeded in 6-well plates, cultured overnight and infected with adenovirus for 48 hrs. 
A non-specific GFP adenovirus with the same multiplicity of infection (MOI) was used 
as a negative control. For loss of function study, ERK5 siRNA (siERK5) was used to 
knock-down ERK5 expression in endothelial cells. ECs were transfected with ERK5 
siRNAs (ON-TARGETplus siRNA, 100 nmol/L; Dharmacon Inc. Lafayette, CO) for 
48hrs using siRNA transfection reagent (DharmaFECT 4; Dharmacon Inc. Lafayette, CO) 
as described before (Zuo et al., 2006). A non-targeting siRNA (siGENOME Non-
Targeting Pool; Dharmacon Inc. Lafayette, CO) with the same concentration of ERK5 
siRNA was used as a negative control. siRNA knock down efficiency was determined by 
real time RT-PCR. 
 
2.2.3 Western blot analysis 
 
Total proteins from ECs were isolated by homogenizing cells in lysis buffer 
(25mM Tris·HCl, pH7.5, 150 mM NaCl, 5 mM MgCl2, 1% NP-40, 1 mM DTT and 5% 
glycerol) and protease inhibitor (complete Mini tablet, Roche, Laval, QC) and 
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phosphatase inhibitor cocktail 1 and 2 (Sigma-Aldrich, Saint Louis, MO). Protein 
concentrations were determined by bicinchoninic acid (BCA) protein assay kit (Pierce, 
Rockford, IL). Thirty µg of protein was resolved by 10% sodium dodecyl sulfate-
polyacrylamide gel electrophoresis and transferred to a PVDF membrane (BIO-RAD, 
Hercules, CA). The membrane was then incubated with the rabbit anti-phospho-ERK5 
antibody (1:1000; Cell Signaling Technology, MA) or rabbit anti-MEF2 antibody (1:200; 
Santa Cruz Biotechnology, Santa Cruz, CA). Horseradish peroxidase-conjugated anti-
rabbit antibody (1:10000; Upstate Biotechnology, Charlottesville, VA) was used for 
detection. The signals from the western blots were visualized with an ECL plus 
chemiluminescence detection kit (Amersham Pharmacia Biotechnology, 
Buckinghamshire, UK).  Blots were stripped with ReBlotTM Plus Strong Antibody 
Stripping Solution (Millipore, Billerica, MA) and reprobed with β-actin antibody (1:1000, 
Santa Cruz Biotechnology, CA) as a control for protein loading.  
 
2.2.4 RNA isolation and cDNA synthesis 
 
TRIzol™ reagent (Invitrogen, Burlington, ON) was used to isolate RNA as 
previously described (Chen et al., 2003a). RNA was extracted with chloroform followed 
by centrifugation to separate the sample into aqueous and organic phases. RNA was 
recovered from the aqueous phase by isopropyl alcohol precipitation and suspended in 
diethylpyrocarbonate-treated water. Total RNA (2-4 µg) was used for cDNA synthesis 
with High Capacity cDNA Reverse Transcription Kit (Applied Biosystem, Foster City, 
CA). The resulting cDNA products were stored at -20°C. 
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2.2.5 Real time reverse transcriptase polymerase chain reaction (RT-PCR) 
 
Real time RT-PCR was performed using the LightCycler (Roche Diagnostics 
Canada, Laval, PQ, Canada) as previously described (Khan et al., 2004). For a final 
reaction volume of 20 µL, the following reagents were added: 10 µL SYBR Advantage 
qPCR Premix (Clontech, Mountain View, CA), 1µL of each forward and reverse 10 µM 
primers (Table 2.1), 7µL H2O, and 1µL cDNA template. The PCR reaction mixture for 
ET-1 consisted of 2.5 µL 10X PCR Buffer (Invitrogen, Carlsbad, CA), 1.25 µL 5mM 
dNTP (Invitrogen, Carlsbad, CA), 1.25 µL 50mM MgCl2, 1 µL of each forward and 
reverse 25 µM primers, 11.3 µL H2O, 0.5 µL 15 mM Taqman probe, 0.2 µL 5U/ µL  
Platinum Taq DNA polymerase (Invitrogen, Carlsbad, CA), and 1µL cDNA template. 
Messenger RNA (mRNA) levels were quantified using the standard curve method. 
Standard curves were constructed by using serially diluted standard template. The data 
were normalized to 18S ribosomal RNA or β-actin to account for differences in reverse 
transcription efficiencies and the amount of template in the reaction mixtures.  
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Table 2.1 Oligonucleotide sequences for real time PCR 
Gene Sequence 5’3’ 
ERK5(human) CTGGCTGTCCAGATGTGAA 
ATGGCACCATCTTTCTTTGG 
ERK5(rat) CTCTGATCCTGCACCTGACA 
GAGCCTGCTCCTTAGGGACT 
KLF2(human) GCACGCACACAGGTGAGAAG 
ACCAGTCACAGTTTGGGAGGG 
KLF2(rat) CTAAAGGCGCATCTGAGGAC 
TTCATGTGCAGAGCCAGGT 
ET-1(human) AAGCCCTCCAGAGAGCGTTAT 
CCGAAGGTCTGTCACCAATGT 
6FAM-TGACCCACAACCGAG-MGBNFQ 
ET-1(rat) GCTCCTGCTCCTCCTTGATG 
CTCGCTCTATGTAAGTCATGG 
β-actin (human 
and rat) 
CCTCTATGCCAACACAGTGC 
CATCGTACTCCTGCTTGCTG 
18S(human and 
rat) 
GTAACCCGTTGAACCCCATT 
CCATCCAACGGTAGTAGCG 
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2.2.6 Animal experiments 
 
Male Sprague-Dawley rats (Charles River) weighing between 200 and 250 g were 
used. Diabetes was induced by a single intravenous injection of streptozotocin (65 mg/kg, 
in citrate buffer, pH 5.6). Age-matched rats were used as controls and given equal 
volume of citrate buffer (Kaur et al., 2006). The animals were monitored for glucosuria 
and ketonuria (Uriscan Gluketo; Yeong Dong, Seoul, South Korea) and were sacrificed 
after 1 month of diabetes. The eyes were immediately enucleated, lens and vitreous 
removed. The retinas were gently peeled off, snap-frozen in liquid nitrogen, and stored at 
-70°C. All animals were cared for according to the American Physiological Society’s 
Guiding Principles in the Care and Use of Animals. All experiments were approved by 
the University of Western Ontario Council on Animal Care Committee.  
 
2.2.7 Statistical analysis 
 
Data were presented as the mean ± standard error of mean. Statistical significance 
of differences between groups were tested using Student’s t test or by using one way 
analysis of variance (ANOVA) followed by LSD post-hoc analysis, as appropriate. A p-
value of 0.05 or less was considered to be significant. All calculations were performed 
using SPSS version 15.0. 
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 2.3 RESULTS 
 
2.3.1 Glucose caused ERK5 activation and upregulation of its downstream 
molecules MEF2 and KLF2 in endothelial cells. 
 
We initially established whether glucose causes activation of ERK5 and alter ET-
1 in the ECs. Western blot analysis demonstrated ERK5 activation following 25 mmol/L 
glucose treatment in HUVECs (Figure 2.1A). Increased phospho-ERK5 (pERK5) was 
noted after 5 minutes of glucose exposure and peaked at 15 minutes (15’). Activation of 
ERK5 lasted up to 12 hours (12h).  Increased ERK5 phosphorylation was not seen after 
24 or 48 hrs of glucose exposure. Simultaneously transcription factor MEF2, a direct 
substrate of ERK5, was increased after high glucose exposure (Figure 2.1A). Real time 
RT-PCR showed that ERK5 mRNA as well as its downstream molecule KLF2 was 
upregulated after 30 mins of glucose exposure (Figure 2.1B and C).  
 
In parallel, we measured glucose-induced ET-1 mRNA expression. Exposure to 
high levels of glucose for 24 hrs caused ET-1 mRNA upregulation in HUVECs (Figure 
2.1D), consistent with previous studies (Apostolova et al., 2001;Chen et al., 2000). It is to 
be noted that such ET-1 mRNA upregulation was not seen following short term glucose 
exposure when ERK5 was activated (data not shown). To study the role of ERK5 
activation on ET-1 expression, gain and loss of function studies were performed. 
 
69 
 
 
Figure 2.1 Alteration of ERK5 signaling and ET-1 expression after high glucose 
treatment 
A) Western blot analyses showing glucose-induced phosphorylation of ERK5 as detected 
using phopho-ERK5 (pERK5) antibody. Such activation was not observed after 24 hrs.  
ERK5’s downstream molecule MEF2 was also upregulated by high glucose treatment. 
Lower panel (B-D) demonstrate mRNA upregulation of ERK5 and KLF2 (following 30 
mins of 25 mM glucose exposure) and ET-1 (following 24 hrs of 25 mM glucose 
exposure). (mRNAs are expressed as a ratio to 18S, normalized to control, n=5-8/group, 
LG = 5mmol/L glucose, HG= 25mmol/L glucose, * = significantly different from LG) 
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2.3.2 ERK5 upregulation inhibited ET-1 expression in endothelial cells 
 
MEK5 is a specific MAPK kinase for ERK5 (Morimoto et al., 2007;Zhou et al., 
1995;Wang and Tournier, 2006). Hence, we used constitutively active MEK5 (CAMEK5) 
adenovirus to augment ERK5 signaling. To identify a dose-dependent relationship, we 
used two doses of CAMEK5, 20 MOI and 100 MOI. In HUVECs, CAMEK5 not only  
increased phosphorylation of ERK5, but also increased ERK5 transcript. Western blot 
confirmed increased pERK5 after CAMEK5 infection in HUVECs (Figure 2.2A). Real-
time PCR showed that MEK5 mRNA level after CAMEK5 infection was significantly 
higher than that of the GFP control (Figure 2.2B and F). Furthermore mRNA expression 
of ERK5 and KLF2 were also upregulated in HUVECs following CAMEK5 infection 
(Figure 2.2C, D, G and H). The upregulation of ERK5 signaling was more pronounced in 
high dose of CAMEK5 compared with that in the low dose. 
 
Interestingly, ET-1 mRNA showed 37% reduction following ERK5 activation by 
20 MOI CAMEK5 infection (Figure 2.2E). Regulatory role of ERK5 was further 
confirmed with larger dose of adenovirus containing CAMEK5 (100 MOI), which 
dramatically increased MEK5, ERK5, KLF2 (Figure 2.2 F-H) and led to 94% inhibition 
of ET-1 mRNA expression (Figure 2.2I).  
 
To further understand whether ERK5-mediated ET-1 regulation varies between 
ECs of macro and microvasculature, we delivered CAMEK5 to HMVECs. Similar 
regulation of ERK5 on ET-1 was found on HMVECs. Real time RT-PCR showed that 
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CAMEK5 (20 MOI) infection led to slight increase of ERK5 transcript and moderate 
increase of KLF2 transcript in association with 17% inhibition of ET-1 mRNA (Figure 
2.3A-C). Larger dose of adenovirus (100 MOI) resulted in significant increase of ERK5 
and KLF2, with 70% decrease of ET-1 mRNA (Figure 2.3D-F). 
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Figure 2.2 CAMEK5 constitutively activates ERK5 signaling and inhibits ET-1 
expression in HUVECs 
In HUVECs, constitutionally active MEK5 (CAMEK5) caused increased ERK5 
activation as indicated by (A) western blot using phosphor-ERK 5 antibody (upper panel). 
CAMEK5 also caused mRNA upregulation of MEK5, ERK5, KLF2 and downregulation 
of ET-1 (B-I). Such changes were more pronounced using 100 MOI CAMEK (lower 
panel, F-I)  compared to 20 MOI (middle panel, B-E) (mRNAs are expressed as a ratio to 
18S or β-actin, normalized to control, n=5/group, * = significantly different from GFP  
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Figure 2.3 CAMEK5 constitutively activates ERK5 signaling and inhibits ET-1 
expression in HMVECs  
In HMVECs, constitutionally active MEK5 (CAMEK5) caused mRNA upregulation of 
ERK5, KLF2 and downregulation of ET-1 (A-F). Such changes were more pronounced 
using 100 MOI CAMEK (lower panel, D-F) compared to 20 MOI (upper panel, A-C) 
(mRNAs are expressed as a ratio to 18S or β-actin, normalized to control, n=6/group, * = 
significantly different from GFP controls)  
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2.3.3 ERK5 downregulation increased ET-1 expression in endothelial cells 
 
As ET-1 expression was inversely related with ERK5 expression upon high 
glucose treatment, to explore the interaction of ERK5 signaling and ET-1 expression, loss 
of function study was performed in HUVECs using ERK5 siRNA. ERK5 siRNA 
transfection resulted in decreased ERK5 and KLF2 mRNA (Figure 2.4A and B) 
expression, at the same time ET-1 mRNA (Figure 2.4C) increased compared with that of 
control group. Hence, the results in loss of function studies were similar to our finding 
after high glucose treatment.  
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Figure 2.4 ERK5 siRNA transfection elevated ET-1 mRNA 
In HUVECs, ERK5 siRNA transfection resulted in decreased ERK5 (A), KLF2 (B), and 
increased ET-1 mRNA (C). (mRNAs are expressed as a ratio to 18S, normalized to 
control, n=3/group, *=significantly different from control siRNA).  
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2.3.4 Upregulated ERK5 signaling by CAMEK5 suppressed ET-1 expression in both 
basal and high glucose conditions 
 
We further expanded the investigations to find out whether ERK5 upregulation 
can protect endothelial cells in pathological conditions mediated by glucose. Because 
glucose-induced tissue damage is mediated by vasoactive factors such as ET-1, we 
proceeded to examine whether constitutively activation of ERK5 signaling can inhibit 
ET-1 expression under high glucose condition. Real time RT-PCR showed that ET-1 
mRNA was decreased by CAMEK5 after high level of glucose treatment in both 
HUVECs (Figure 2.5A-B) and HMVECs (Figure 2.5C). Two different doses of 
CAMEK5 transduction were applied to HUVECs. Low dose (20MOI) mildly inhibited 
ET-1 mRNA in basal and high glucose conditions (Figure 2.5A). High dose (100MOI) of 
CAMEK5 strongly suppressed ET-1 mRNA. In addition glucose induced-upregulation of 
ET-1 mRNA can be prevented by high dose of CAMEK5 (Figure 2.5B).  
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Figure 2.5 ERK5 signaling upregulation by CAMEK5 inhibited ET-1 expression in 
both basal and high glucose conditions. 
Constitutionally active MEK5 (CAMEK5) inhibited ET-1 mRNA after glucose treatment 
in HUVECs (A,B) and HMVECs (C). Such effects were more pronounced using 100 
MOI CAMEK (B,C)  compared to 20 MOI (A) (mRNAs are expressed as a ratio to 18S 
or β-actin, normalized to control, n=5/group, LG = 5mmol/L glucose, HG= 25mmol/L 
glucose, * = significantly different from GFP control on LG, †= significantly different 
from GFP control on HG ) 
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2.3.5 Similar alterations of ERK5 and ET-1 were observed in the retina of diabetic 
rats 
 
Finally, we examined whether glucose-induced ERK5 alteration occurs in 
association with ET-1 upregulation in an organ affected by chronic diabetic 
complications. We investigated retina from STZ-induced diabetic rats after 1 month of 
diabetes. Diabetic rats were hyperglycemic, glycosuric and showed loss of body weight 
compared to the age- and sex-matched control animals (Table 2.2). Retinal tissue after 
one month of diabetes showed decreased ERK5 mRNA (Figure 2.6A) in association with 
ET-1 mRNA upregulation (Figure 2.6B).  
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Table 2.2 Animal monitoring 
Groups Body weight  
(g) 
Blood glucose 
(mmol/L) 
Controls 445.7±17.4 6.3±0.4 
Diabetics 323±25.4* 28.5±4.1* 
n=5/group, * = significantly different from the controls 
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Figure 2.6 ERK5 and ET-1 mRNA expression in retinal tissues of diabetic rats 
Diabetes caused downregulation of ERK5 in the rat retina (A) in association with 
upregulation of ET-1 mRNA (B) (mRNAs are expressed as a ratio to 18S, normalized to 
control, n=5/group, * = significantly different from controls) 
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2.4 DISCUSSION 
 
 
This study demonstrated a novel mechanism regulating ET-1 gene expression in 
hyperglycemia. We have shown that ERK5 signaling pathway is activated by glucose in 
the ECs.  Moreover, in two EC types we have demonstrated, using constitutively active 
MEK5 and ERK5 siRNA, that ERK5 negatively regulates ET-1 mRNA expression and 
that CAMEK overexpression can effectively downregulate glucose-induced ET-1 mRNA 
expression. Furthermore similar downregulation of ERK5 and ET-1 upregulation were 
noted in the retina of diabetic animals. 
 
We have previously demonstrated the importance of glucose-induced ET-1 
upregulation and its pathogenetic role in chronic diabetic complications (Chen et al., 
2002;Chen et al., 2003a;Evans et al., 2000;Chen et al., 2003b). We have demonstrated 
that such ET-1 upregulation leads to blood flow and permeability alterations as well as 
increased extracellular matrix protein production (Chen et al., 2000;Chen et al., 
2003b;Evans et al., 2000). Glucose-induced metabolic alterations cause ET-1 
upregulation in diabetes through PKC activation and increased non-enzymatic glycation 
(Chen et al., 2000;Chen et al., 2003a). Current study indicates a novel mechanism of ET-
1 gene regulation in this context through ERK5 activation.  We have further shown in this 
study that such regulation of ET-1 gene may occur via MEF2 and KLF2. MEF2 and 
KLF2 are both well established downstream mediators of the effects of ERK5 (Olson, 
2004). It has been reported that ERK5 and KLF2 upregulation increase eNOS expression 
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and subsequent nitric oxide (NO) production (Parmar et al., 2006;Woo et al., 2008). It is 
possible that such increase in NO may reduce ET-1 production. However possibilities of 
other co-existing mechanisms cannot be excluded. It is interesting that although negative 
regulation of ERK5 on ET-1 was observed in both EC lines, such responses were more 
robust in the HUVECs. Exact reasons for this discrepancy are not clear. However, ECs 
from various sources, macro or microvasculature, are known to behave differently (King 
et al., 1983;Sachidanandam et al., 2006). In addition, variable number of adenovirus 
receptors may also account for such findings. 
 
In keeping with our data, a previous study showed glucose-induced ERK5 
activation in pulmonary artery ECs (Liu et al., 2000). However, the effects of ERK5 
activation by glucose were not previously explored.  ERK5 regulates a wide range of 
cellular processes and ablation of ERK5 leads to embryonic lethality (Hayashi et al., 
2004). ERK5 is different from other MAPKs because of its unique C-terminal, which 
contains transcriptional activation domain. Transcriptional activation can enhance the 
effect of ERK5 signaling (Morimoto et al., 2007). Hence, we examined ERK5 
transcription in our study which paralleled its downstream effects. Expression of this 
transcription domain is sufficient to drive MEF2 and regulate MEF2-dependent gene 
expression (Kasler et al., 2000). The importance of transcriptional activation ERK5 have  
also been previously demonstrated by its effects on inhibition of ERK5 SUMOylation 
and prevention of diabetes-mediated left ventricular dysfunction (Shishido et al., 2008). 
However, ERK5 also activates signaling by traditional phosphorylation (Kato et al., 
2000). Studies have shown that the activated kinase activity of ERK5 undergoes 
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autophosphorylation on its most C-terminal region, which is required for the C-terminal-
half to enhance the ERK5 activity (Morimoto et al., 2007). In this study we have 
demonstrated both increased ERK5 transcription and phosphorylation. These data 
indicate that both mechanisms may be operating in glucose-induced ET-1 upregulation. 
 
In summary, this is the first study that reveals ERK5 negatively regulates ET-1. 
Although this study was done in the context of chronic diabetic complications, it is 
possible that this mechanism is of importance in other endothelial disease processes. As 
ERK5 regulates multiple pathways, it may also provide an attractive target for drug 
development in diseases affecting endothelial injury and vasculature.  However further 
studies are necessary for in detail characterization of these mechanisms. 
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CHAPTER 3: ERK5 contributes to VEGF alteration in diabetic retinopathy 
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3.1 INTRODUCTION 
 
Diabetic retinopathy (DR) is a devastating complication of diabetes, 
manifesting primarily as vascular structural and functional changes in the retina, and 
eventually leading to vision loss. DR is the most common cause of blindness in North 
America in the 25-74 years age group (Aiello et al., 1998). Glucose-induced increased 
production of vasoactive factors are characteristics of all chronic diabetic 
complications including DR. Vascular endothelial growth factor (VEGF) is a key 
vasoactive factor, which is upregulated in the retina in diabetes. VEGF is an important 
mediator of increased vascular permeability in early DR and a major contributor of 
retinal neovascularization in late proliferative DR (Aiello et al., 1998;Boulton et al., 
1998;Lutty et al., 1996;Malecaze et al., 1994). VEGF mRNA expression is increased 
in the neovascular membranes from diabetic patients obtained by vitrectomy 
compared to those removed from the non-diabetic individuals (Malecaze et al., 1994). 
Augmented VEGF protein production was also observed in human retina in diabetes 
using immunohistochemistry (Lutty et al., 1996;Boulton et al., 1998). We and others 
have demonstrated increased VEGF expression in the retina of streptozotocin-induced 
diabetic rat model increases microvascular permeability (Cukiernik et al., 
2004;Hammes et al., 1998). In a murine model of ischemic retinopathy, inhibition of 
VEGF has also been shown to suppress retinal neovascularization (Aiello et al., 1995). 
Furthermore exposure of endothelial cells (ECs) to high glucose causes increased 
VEGF expression (Chen et al., 2000;Gao et al., 2008). VEGF mRNA and protein 
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expression are stimulated by long term high glucose treatment in bovine 
microvascular retinal ECs(Wu et al., 2008). Previous studies in our lab have 
demonstrated that VEGF interacts with other vasoactive factors such as endothelin-1 
(ET-1) in mediating glucose-induced increased permeability in the ECs (Chen et al., 
2000;Cukiernik et al., 2004). These data indicate that VEGF plays an important role 
in causing increased vascular permeability and angiogenesis in DR (Lutty et al., 
1996;Boulton et al., 1998). Several glucose-induced signaling mechanisms such as 
protein kinase C (PKC) activation, non-enzymatic glycation and mitogen-activated 
protein kinase (MAPK) activation are instrumental in causing glucose-induced 
alteration of vasoactive factors in diabetes (Khan and Chakrabarti, 2007).  
 
ERK5, also known as big MAPK1 (BMK1), was identified as a member of the 
MAPK family in 1995 (Lee et al., 1995;Zhou et al., 1995). ERK5 is a protein of 816 
amino acid residues with a large COOH terminal. BMK1 is different from other 
MAPK as it has a transcriptional activation domain. MAPK/ERK kinase 5 (MEK5) is 
the specific MAPK kinase for ERK5. ERK5 is highly expressed in the ECs (Yan et al., 
1999). Studies in ERK5 knockout mice have shown that the ERK5 pathway is critical 
for endothelial function and for maintaining blood vessel integrity (Hayashi et al., 
2004). In addition, ERK5 signaling mediates stress response in the ECs (Pi et al., 
2004;Yan et al., 1999). More recently, studies have shown that ERK5 signaling 
controls migration and morphology of the ECs (Spiering et al., 2009). 
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It has been demonstrated that in the non-diabetic conditions, ERK5 have a 
regulatory role on VEGF expression (Pi et al., 2005;Sohn et al., 2002;Sohn et al., 
2005) . In mouse, mutant ERK5 gene (homozygous knockout) increases expression of 
VEGF mRNA and protein (Sohn et al., 2002;Sohn et al., 2005). Moreover, ERK5 
represses VEGF expression in bovine lung microvascular ECs (Pi et al., 2005). 
Investigations have shown that overexpression of Krupple-like factor 2 (KLF2), a 
target gene of ERK5, inhibited VEGF receptor promoter activation (Bhattacharya et 
al., 2005). KLF2 overexpression also counteracts VEGF-mediated inflammatory 
responses in the ECs (Sako et al., 2009). In addition, microarray studies have revealed 
that KLF2 overexpression decreases mRNA expression of human VEGF receptor 2 
(Boon et al., 2007;Dekker et al., 2006). Hence, it is possible that ERK5 through KLF2 
may also have a regulatory role on the production of VEGF in DR. However such 
possibilities haven’t been investigated. Here, we examined the mechanisms of 
glucose-induced ERK5-mediated regulation of VEGF in the ECs and in the retina of 
diabetic rats. We further explored the significance of such changes in DR. 
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3.2 MATERIALS AND METHODS 
 
3.2.1 Cell culture 
 
A dermal-derived human microvascular endothelial cell (HMVEC) was 
obtained from Lonza (Walkersville, MD). HMVECs were grown in endothelial cell 
basal medium 2 (EBM-2, Lonza, Walkersville, MD) containing human epidermal 
growth factor (hEGF), 1‰; Hydrocortisone, 0.4‰; gentamycin, 1‰; fetal bovine 
serum (FBS), 10%; vascular endothelial growth factor (VEGF), 1‰; human fibroblast 
growth factor - basic (hFGF-B), 4‰; long R3 insulin-like growth factor (R3-IGF-1), 
1‰; Ascorbic Acid, 1‰. In EBM2, the glucose concentration was 5 mmol/l. Cells 
were grown in 25 cm2 tissue culture flasks and maintained in a humidified atmosphere 
containing 5% CO2 at 37ºC. Cells at 80% confluence were growth arrested by 
incubation in serum-free medium overnight prior to treatment with high glucose (25 
mmol/L D-glucose) or osmotic control (L-glucose) of the same concentration.  
 
3.2.2 Transfection of endothelial cells with siRNAs 
 
HMVECs were seeded in 6-well plates at a density of 1x105 and cultured for 
24 hours. Cells were transfected with ERK5 siRNA (siERK5) (ON-TARGETplus 
siRNA, 100 nmol/L; Dharmacon Inc. Lafayette, CO), or a non-targeting siRNA 
(control siRNA) (siGENOME Non-Targeting Pool; Dharmacon Inc.) with the same 
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concentration of ERK5 siRNA according to the manufacture’s instruction. ERK5 
siRNA and control siRNA were transfected for 48 hours using siRNA transfection 
reagent (DharmaFECT 4; Dharmacon Inc.) as described before (Zuo et al., 2006). 
Knock down efficiency was determined by real time RT-PCR. 
 
3.2.3 Viral gene transfer 
 
Constitutively active human recombinant MEK5 (CAMEK5) adenovirus was 
obtained from Cell Biolabs (San Diego, CA). The dual phosphorylation site 
S311/S315 in the CAMEK5 mutant has been changed to D311/D315. HMVECs were 
plated 24 hours before on a 6-well plate. HMVECs were infected with CAMEK5 or a 
non-specific GFP adenovirus (Cell Biolabs) at the same multiplicity of infection for 
48 hours as described before (Wu et al., 2010b). Transduction efficacy was measured 
by western blot analysis. 
 
 
3.2.4 RNA isolation and cDNA synthesis 
 
RNA from HMVECs and rat retina tissues were isolated using TRIzol™ 
reagent (Invitrogen, Burlington, ON) as previously described (Chen et al., 2003). 
RNA concentration was measured on a spectrophotometer (Gene Quant, Pharmacia 
Biotech, USA). First-strand cDNA was made by using High Capacity cDNA Reverse 
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Transcription Kit (Applied Biosystem, Foster City, CA). The resulting products were 
stored at −20◦C. 
 
3.2.5 Real time reverse transcriptase polymerase chain reaction (RT-PCR) 
 
Real time RT-PCR was performed using LightCycler (Roche Diagnostics 
Canada, Laval, QC) to quantify the mRNA expression of ERK5, MEF2C, KLF2 and 
VEGF as previously described (Khan et al., 2004). For a final reaction volume of 
20µL, the following reagents were added: 10µL of SYBR Advantage qPCR Premix 
(Clontech, Mountain View, CA), 1µL forward and reverse primer respectively (Table 
3.1), 7µL H2O, and 1µL cDNA template. To optimize the amplification of the genes, 
melting curve analysis (MCA) was used to determine the melting temperature (Tm) of 
specific products and primer dimers. Standard curve method was used to quantify 
mRNA levels. Standard curves were constructed by using serially diluted standard 
template. The data were normalized to housekeeping gene β-actin or 18S ribosomal 
RNA to account for differences in reverse transcription efficiencies and amount of 
template in the reaction mixtures. 
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Table 3.1 Oligonucleotide sequences for real time RT-PCR 
Gene  Sequence 5’3’  
ERK5(human) CTGGCTGTCCAGATGTGAA 
ATGGCACCATCTTTCTTTGG 
MEF2C(human) TACAACGAGCCGCATGAGAG 
CCTGTGTTACCTGCACTTGG 
KLF2(human) GCACGCACACAGGTGAGAAG 
ACCAGTCACAGTTTGGGAGGG 
VEGF(human) GGCCTCCGAAACCATGAACTTTCTGCT 
GCATGCCCTCCTGCCCGGCTCACCGC 
VEGF(rat) CTGCTGTCTTGGGTGCATTGG 
CACCGCCTTGGCTTGTCACAT 
β-actin (human 
and rat) 
CCTCTATGCCAACACAGTGC 
CATCGTACTCCTGCTTGCTG 
18S(human and 
rat) 
GTAACCCGTTGAACCCCATT 
CCATCCAACGGTAGTAGCG 
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3.2.6 Protein extraction and western blot analysis 
 
After high glucose treatment or CAMEK5 transduction described above, 
HMVECs were washed twice with cold phosphate-buffered saline (PBS) and lysed in 
lysis buffer (25 mmol/L Tris·HCl, pH7.5, 150 mmol/L NaCl, 5 mmol/L MgCl2, 1% 
NP-40, 1 mmol/L DTT and 5% glycerol) and protease inhibitor (complete Mini tablet, 
Roche, Laval, QC) and phosphatase inhibitor cocktail 1 and 2 (Sigma-Aldrich, Saint 
Louis, MO). The total protein concentration was measured using bicinchoninic acid 
(BCA) protein assay kit (Pierce, Rockford, IL) according to the manufacturer’s 
instructions.  
 
Total protein (30µg) was resolved in 10% sodium dodecyl 
sulfate-polyacrylamide (SDS) gel electrophoresis transferred to a PVDF membrane 
(Bio-Rad, Hercules, CA). The membrane was then incubated with rabbit 
anti-phospho-ERK5 antibody, ERK5 antibodies (1:1000; Cell Signaling Technology, 
MA) or β-actin antibody (1:1000, Santa Cruz Biotechnology, Santa Cruz, CA) as 
described previously (Wu et al., 2010b). The signals from western blots were obtained 
using horseradish peroxidase-conjugated secondary anti-rabbit (1:10000; Upstate 
Biotechnology, Charlottesville, VA) or anti-mouse antibody (1:10000; Santa Cruz 
Biotechnology) and visualized with an ECL plus chemiluminescence detection kit 
(Amersham Pharmacia Biotechnology, Buckinghamshire, UK). Blots were quantified 
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by densitometry using MochaTM software (SPSS, Chicago, IL) and the data expressed 
as a ratio of phosphor-Erk5 to β-actin. 
 
3.2.7 In vitro angiogenesis assay 
 
The angiogenic responses to high glucose (25mmol/L) and ERK5 siRNA 
transfection were assessed using an in vitro Matrigel analysis. Following appropriate 
treatment, HMVECs were seeded in 96-well culture plates precoated with 
ECMatrixTM (In Vitro Angiogenesis Assay Kit, Milipore, Billerica, MA) at 1×104 
cells/well. Cells were maintained in serum free medium at 37ºC for 6hrs. The tube 
like structures were visualized by a Leica inverted light microscope. Images were 
captured with Infinity Capture software Version 3.5.1 at ×10 magnification after 6hrs 
incubation. To quantify the image of tube formation, branch points were counted in 
several random microscopic fields (3-5) per sample and the values averaged. At least 
3 different cultures were counted per experimental group. The data were expressed as 
number of branch points per100x field.  
 
3.2.8 Animal experiments 
 
Male Sprague-Dawley rats (Charles River) weighing between 200 and 250 g 
were used. Diabetes was induced by a single intravenous injection of streptozotocin 
(65 mg/kg, in citrate buffer, pH 5.6). Age and sex matched rats were used as controls 
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and given equal volume of citrate buffer (Kaur et al., 2006). The animals were 
monitored for glucosuria and ketonuria (Uriscan Gluketo; Yeong Dong, Seoul, South 
Korea). All diabetic rats were implanted with slow release insulin implants to prevent 
ketosis (approximately 2 U/day) (LinShin, Scarborough, ON, Canada). They were 
sacrificed after 4 month of diabetes. We have previously demonstrated that they 
develop diabetes induced tissue damage in the retina and kidney at this time (Xu et al., 
2008). The eyes were immediately enucleated, lens and vitreous removed. The retinas 
of the right eye were gently peeled off, snap-frozen in liquid nitrogen, and stored at 
-70°C. The left retinas were fixed in 4% paraformaldehyde (PFA), as described before 
(Cukiernik et al., 2004). All animals were cared for according to the Association for 
Research in Vision and Ophthalmology’s Guiding Principles in the Care and Use of 
Animals. All experiments were approved by the University of Western Ontario 
Council on Animal Care Committee. 
 
3.2.9 Immunohistochemistry 
 
Formalin-fixed retinal tissues were embedded in paraffin, sectioned at 4 µm 
thickness and placed on positively charged slides for phospho-ERK5 (pERK5) 
immunohistochemical staining. Briefly, the sections were incubated with rabbit 
anti-pERK5 antibody (Invitrogen, Carlsbad, CA, USA) at 1:200 dilutions overnight at 
4ºC, followed by incubation with labeled polymer-HRP anti-rabbit antibody (Dako 
North America, Carpinteria, CA, USA) for 30 minutes at room temperature. 
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Visualization was conducted using diaminobenzidine (DAB, Dako North America, 
Carpinteria, CA, USA) as HRP substrate. Slides were counterstained with 
Hemotocylin. Staining with non-immune rabbit serum instead of primary antibodies 
was used as negative controls. Images were recorded by an Olympus BX51 
microscope (Olympus Canada Inc, ON, Canada) with Northern Eclipse software 
(Empix Inc, ON, Canada). 
 
3.2.10 Statistical analysis 
 
Data were presented as the mean ± standard error of mean. Statistical 
significance of difference between groups was tested using Student’s t test or if there 
were more than two groups, using one way analysis of variance (ANOVA) followed 
by LSD post-hoc analysis. A p-value of 0.05 or less was considered to be significant. 
All calculations were performed using SPSS version 15.0. 
 110 
3.3 RESULTS 
 
 
3.3.1 Glucose caused ERK5 alteration and VEGF upregulation 
 
 
We initially established whether in the ECs, glucose causes any alteration of 
ERK5 signaling. No change in the mRNA expression of ERK5 and its downstream 
molecules MEF2C, KLF2, or VEGF were seen after exposure of the cells to 
25mmol/L glucose (HG) for 1 hour compared to 5 mmol/L glucose (LG) (Figure 
3.1C-F). L-glucose was used as an osmotic control (OC). In keeping with real time 
PCR result, western blot analysis showed that phosphor- and total ERK5 were not 
altered within 1 hr glucose treatment (Figure App-1). Following 24 hrs of glucose 
exposure, ERK5 signaling was significantly activated as evidenced by increased 
phosphorylation (Figure 3.1A, B) and mRNA expression of ERK5 (Figure 3.1C) and 
augmented mRNA expression of MEF2C (Figure 3.1D) and KLF2 (Figure 3.1E), 
which are downstream mediators of ERK5 signaling. Interestingly, at this time point 
there were no increases of VEGF mRNA expression (Figure 3.1F). However, with 
increased duration of high glucose treatment (48 hrs), ERK5 phosphoration and 
mRNA expression (Figure 3.1A-C) as well as MEF2C and KLF2 mRNA expression 
(Figure 3.1D, E) were decreased, while VEGF mRNA expression was increased 
(Figure 3.1F). Similar results were also observed after 72hrs HG treatment (data not 
shown). Since expression of total ERK5 was also changed after glucose treatment, 
western blot of pERK5 was normalized to β-actin. To further delineate the 
mechanistic role and significance of glucose-induced ERK5 activation, especially 
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with its regulatory effects on VEGF expression, gain and loss of function studies were 
performed. 
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Figure 3.1 VEGF mRNA was inversely related to ERK5 signaling pathway in 
endothelial cells treated with high glucose 
A) Representative western blot showing increased pERK5 and total ERK5 after 24hrs 
HG treatment which subsequently decreased after 48hrs. B) Densitometric 
quantification of pERK5 expression. C-F) Real-time PCR showed that following 
incubation in HG., ERK5, MEF2C and KLF2 mRNA expression were increased after 
24hrs and then were decreased after 48hrs. On the other hand, VEGF mRNA 
expression did not increase until after 48hrs HG treatment. LG=5mmol/L D-glucose; 
OC=osmotic control, 25mmol/L L-glucose; HG=25mmol/L D-glucose. [Data in ‘B’ 
are expressed as a ratio to β–actin. mRNAs are expressed as a ratio to 18S, 
normalized to controls, *: significantly different from LG, n=3-6/group.]  
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3.3.2 ERK5 downregulation led to increased VEGF expression  
 
Our initial investigation indicated that VEGF mRNA expression was inversely 
related to ERK5 activation following high glucose treatment. To further explore the 
interaction of ERK5 signaling and VEGF expression, loss of function study was 
performed in the HMVECs using ERK5 siRNA. ERK5 siRNA was transfected to 
endothelial cells to knock down ERK5 gene. Real-time RT-PCR analyses 
demonstrated that such transfection led to >70% reduction of ERK5 mRNA 
expression (Figure 3.2A). ERK5 downstream substrates, MEF2C and KLF2, were 
also significantly reduced (Figure 3.2B, C). As expected, VEGF mRNA expression 
was increased following ERK5 siRNA transfection measured by real-time RT-PCR 
(Figure 3.2D). To further study the effect of ERK5 knockdown on glucose-induced 
VEGF upregulation, HMVECs were transfected with ERK5 siRNA and then treated 
with high glucose for short period (24hrs). Results showed that ERK5 siRNA 
transfection abolished high glucose-induced increase of ERK5, MEF2C and KLF2 
mRNA (Figure 3.2A-C), whereas it promoted upregulation of VEGF mRNA (Figure 
3.2D).  
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Figure 3.2 ERK5 siRNA abolished ERK5 activation induced by high glucose and 
promoted the increase in VEGF in endothelial cells 
ERK5 siRNA transfection reduced basal (5mmol/L, LG) and glucose-induced 
(25mmol/L, HG) mRNA expression of ERK5 (A), MEF2C (B), KLF2 (C) in 
endothelial cells after 24 hrs of HG treatment. On the other hand, ERK5 siRNA 
transfection augmented VEGF mRNA expression (D). [Data are expressed as a ratio 
to β-actin, normalized to controls, * = significantly different from control siRNA in 
LG, ** = significant difference from control siRNA in HG, n=6/group] 
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3.3.3 Functional significance of glucose-induced and ERK5-mediated VEGF 
upregulation 
 
We further expanded the investigations to examine functional significance of 
glucose-induced and ERK5-mediated VEGF expression. As glucose-induced VEGF 
upregulation plays an important role in neovascularization in proliferative DR, we 
examined whether alteration of ERK5 and subsequent change in VEGF has any 
effects on endothelial tube formation using and an in vitro angiogenesis assay. High 
glucose treatment (48hrs) stimulated branching and tube formation in endothelial cells 
transfected with control siRNA (Figure 3.3A, B), which was similar as our finding in 
endothelial cells without transfection (data not shown). Glucose-induced tube 
formation paralleled increased VEGF mRNA expression measured by real-time PCR 
(Figure 3.1E). Endothelial cells transfected with ERK5 siRNA rapidly formed 
capillary-like tube structures (Figure 3.3C). High glucose treatment further augmented 
the number and size of tube-like structure formation (Figure 3.3D).  Quantification 
of tube formation was shown in Figure 3.3E. Such increase in tube formation was 
associated with pronounced VEGF mRNA expression (Figure 3.2D). These results 
suggest that decreased ERK5 stimulates angiogenesis by increasing VEGF 
expression. 
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Figure 3.3 ERK5 siRNA enhanced tube formation in ECs under normal and high 
glucose conditions. 
A-D) Representative phase-contrast photographs of in vitro angiogenesis assay 
showing tube formation in ECs. Such tube formations were pronounced following 
ERK5 siRNA transfection (C, D), compared with control siRNA transfection (A, B), 
both in 5mmol/L (LG) or 25 mmol/L (HG) glucose. original magnification at 100X. E: 
quantification of tube formation by counting branch points of tube-like structures 
confirmed stimulatory effect of ERK5 siRNA on tube formation. [Data are expressed 
as number of branch points per 100x field, * = significantly different from control 
siRNA in LG, † = significant difference from control siRNA in HG, n=3/group] 
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3.3.4 ERK5 upregulation inhibited VEGF expression in endothelial cells 
 
We then investigated whether ERK5 upregulation can protect endothelial cells 
in pathological conditions mediated by glucose. As glucose-induced tissue damage is 
mediated by vasoactive factors such as VEGF, we proceeded to examine whether 
glucose-induced upregulation of VEGF mRNA can be prevented by constitutively 
active MEK5 (CAMEK5). 
MEK5 is a specific MAPK kinase for ERK5 (Morimoto et al., 2007;Zhou et 
al., 1995;Wang and Tournier, 2006). Hence, use of CAMEK5 adenovirus to 
upregulate ERK5 signaling is a rational approach. CAMEK5 not only activated ERK5 
phosphorylation, but also augmented ERK5 transcription (Figure 3.4A,B). Western 
blot confirmed increased pERK5 after CAMEK5 infection in HMVECs (Figure 3.4A). 
Real-time RT-PCR showed that ERK5 mRNA level after CAMEK5 infection was 
significantly higher than that of GFP control and untreated control (Figure 3.4B). 
ERK5 activation caused upregulation of KLF2 mRNA expression (Figure 3.4C) and 
downregulation of VEGF mRNA expression (Figure 3.4D).  
To study the effect of CAMEK5 on glucose-induced VEGF expression, 
HMVECs was infected with CAMEK5 and then treated with high glucose for 24hrs. 
VEGF mRNA was slightly decreased by CAMEK5 induced activation of ERK5 in LG 
groups, while constitutively activation of ERK5 by CAMEK5 infection led to a 
significant decrease of VEGF after HG treatment (Figure 3.4E). 
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Figure 3.4 Upregulation of ERK5 signaling by CAMEK5 inhibited VEGF mRNA 
expression in basal as well as high glucose conditions 
In ECs, constitutionally active MEK5 (CAMEK5) caused increased ERK5 
phosphorylation as indicated by (A) Western blot using phosphor-ERK 5 antibody. 
CAMEK5 also caused mRNA upregulation of ERK5 (B), KLF2 (C) and 
downregulation of VEGF (D). Twenty-four hours exposure of 25mmol/L of glucose 
(HG) significantly decreased VEGF mRNA expression after CAMEK5 infection (E). 
[mRNAs are expressed as a ratio to 18S, normalized to control, n=5/group, *: 
significantly different from untreated or GFP controls, †: significantly different from 
other groups] 
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3.3.5 Reduced ERK5 activation was associated with increased VEGF mRNA 
expression in retinas of diabetic rats 
 
From the perspective of DR, it is important to examine whether the alterations 
demonstrated in the endothelial cells are indeed important in a clinically relevant 
model of diabetic retinal microangiopathy. Hence, we investigated retinas from a well 
established model of diabetic retinal microangiopathy. Phospho-ERK5 
immunohistochemical staining was performed in the retinal tissues of STZ-induced 
diabetic rats after 4 month of follow-up. Diabetic animals showed increased blood 
glucose levels, reduced body weight gain, glucosuria and occasional ketonuria (data 
not shown). Positive pERK5 staining was localized in the ganglion cell layer and in 
the inner nuclear layer. Microscopic examination further revealed that such positivity 
was in the microvasculature, as well as in other cells. The number of positive cells 
and the intensity of staining were reduced in the retina of diabetic animals compared 
with that of controls (Figure 3.5A-B). We also examined the mRNA expression of 
ERK5, KLF2 and VEGF in retinal tissues of 4-month diabetic and control rats. 
Real-time RT-PCR showed that ERK5 mRNA expression in diabetic group was below 
detected level (data not shown). In parallel, mRNA expression of KLF2, a 
downstream molecule of ERK5 signaling, in diabetic group was markedly lower than 
that of control group (Figure 3.5C). In keeping with our previous data from our lab 
and others, real-time PCR analyses demonstrated a significant increase of VEGF 
mRNA expression in the retina of diabetic rats (Figure 3.5D). 
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Figure 3.5 Decreased ERK5 activation was associated with increased VEGF 
mRNA expression in the retina of diabetic rats 
Immunohistochemical staining of pERK5 in the retina showing reduced pERK5 
protein expression in the retina of diabetic (B) rats compared to the control animals 
(A). Positive pERK5 staining was localized in the ganglion cell and inner nuclear 
layers (arrows). Inset is an enlarged view of a microvessel showing positive pERK5 
staining in the endothelial cells. Real-time PCR analysis showed reduced KLF2 (C) 
and augmented VEGF (D) mRNA expression in the retina of diabetic rats compared 
to the controls. [Original magnification at 100 x. mRNAs are expressed as a ratio to 
18S, normalized to control, n=5/group, *: significantly different from controls]. 
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 3.4 DISCUSSION 
 
Here we have demonstrated a novel mechanism of glucose-mediated VEGF 
gene upregulation in diabetes. We have shown that in the ECs, glucose causes 
transient activation of ERK5 followed by deactivation. Reduced activity of ERK5 was 
associated with upregulation of VEGF mRNA and angiogenesis. We have confirmed 
such negative regulation of ERK5 on VEGF using ERK5 silencing and 
overexpression. Furthermore, we have found similar alteration of ERK5 and VEGF in 
the retina of diabetic animals. 
 
A substantial body of evidence indicates that VEGF is a major angiogenic 
factor involved in DR (Pe'er et al., 1995;Ray et al., 2004). MAPK signaling pathway 
plays an essential role in modulating expression of VEGF (Depeille et al., 2007). 
Constitutive activation of ERK1/2 elevated expression of VEGF mRNA (Milanini et 
al., 1998). Overexpression of p38 and JNK activation increased half-life of VEGF 
mRNA (Pages et al., 2000). In addition, knockout animal study showed that JNK 
regulated VEGF expression at the transcriptional level in hypoxia-induced retinal 
VEGF production (Guma et al., 2009). A recent publication revealed that Wnt 
signaling is activated in DR and upregulates VEGF expression (Chen et al., 2009). On 
the other hand ERK5, as demonstrated in this paper, is the only protective signaling 
that is activated by high glucose. In this study, we examined the effect of ERK5 on 
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high glucose induced-VEGF expression and demonstrated a novel pathway that 
potentially contributes to VEGF expression and subsequent angiogenesis in DR.  
 
ERK5 is different from other MAPKs because of its unique C-terminal, which 
contains transcriptional activation domain. Transcriptional activation can enhance the 
effect of ERK5 signaling (Morimoto et al., 2007). Hence, we examined ERK5 
transcription in our study which paralleled its downstream effects. Expression of this 
transcription domain is sufficient to drive MEF2 and regulate MEF2 dependent gene 
expression (Kasler et al., 2000). The importance of transcriptional activation ERK5 
have also been previously demonstrated by its effects on inhibition of ERK5 
SUMOylation and prevention of diabetes-mediated left ventricular dysfunction 
(Shishido et al., 2008). However, ERK5 also activates signaling by traditional 
phosphorylation (Kato et al., 2000). Studies have shown that the activated kinase 
activity of ERK5 undergoes autophosphorylation on its most C-terminal region, 
which is required for the C-terminal-half to enhance the ERK5 activity (Morimoto et 
al., 2007). In this study, we have demonstrated both attenuated ERK5 transcription 
and phosphorylation in high glucose-treated endothelial cells. Our data indicate that 
both mechanisms may be operating in glucose-induced VEGF upregulation. 
 
It has been previously reported that MEF2-KLF2 counteracted 
VEGF-mediated inflammatory responses in endothelial cells (Sako et al., 2009). In 
addition, KLF2 a downstream molecule of ERK5, is a transcriptional regulator of 
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angiogenesis, and overexpression of KLF2 counteracts VEGF-mediated angiogenesis 
due to potent inhibition of VEGFR2 expression and promoter activity (Bhattacharya 
et al., 2005). Our study found that reduced ERK5, MEF2C and KLF2 expression were 
along with increased VEGF level after 48hrs glucose exposure (Figure 3.1). On the 
other hand, VEGF upregulation was seen after 24hrs even when ERK5 is activated. 
Exact reason for such findings is not clear. Possible explanation may include other 
regulatory factors and cell specific factors, which need further characterization. 
Nevertheless, ERK5 siRNA transfection significantly reduced MEF2C and KLF2 
mRNA expression (Figure 3.4), suggesting that ERK5 negatively regulates VEGF 
through MEF2C and KLF2 upon high glucose treatment. Under hypoxic conditions, 
ERK5 inhibits VEGF via hypoxia inducible factor 1 α (HIF1α) in endothelial cells (Pi 
et al., 2005). In addition, it has been shown that KLF2 inhibits HIF1a and 
hypoxia-mediated angiogenesis (Kawanami et al., 2009). High glucose induces a state 
of pseudo-hypoxia in diabetic complications (Van den Enden et al., 1995;Williamson 
et al., 1993). It is therefore possible that depletion of ERK5/KLF2 signaling may 
promote high glucose-induced angiogenesis via HIF1a. However, such notion has to 
be further established by specific experiments. 
 
In keeping with our finding it has been demonstrated that ERK5 activation is 
induced transiently by high glucose in endothelial cells, which ultimately decreased 
after long term treatment (Liu et al., 2000). As following long term glucose exposure 
in ECs and in the retina of chronically diabetic animals, similar pattern of ERK5 and 
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VEGF were seen, it is possible that in long term diabetes inhibitory effects of ERK5 is 
lost, leading to VEGF upregulation. In this study we have seen VEGF upregulation 
after 48hrs. This is in keeping with studies in endothelial cells from other sources 
(Gao et al., 2008;Wu et al., 2010a). Some studies have demonstrated VEGF 
upregulation following a short period of glucose exposure. Various sources of cells 
and culture conditions may in part be responsible for such discrepancy. In addition, 
simultaneously other mechanisms may also be responsible for glucose-induced VEGF 
upregulation. Both PKC and ERK1/2 activation have been demonstrated to regulate 
VEGF in glomerular podocytes (Hoshi et al., 2002).  In this study, we observed no 
significant downregulation of VEGF after 24hrs glucose treatment at which point 
ERK5 is activated. This suggests that other mechanisms mentioned above may also 
modulate glucose-induced VEGF, further investigation is required to delineate of the 
relationship of ERK5 and other signaling pathways.  
 
It is well established that oxidant and shear stress can regulate ERK5 alteration. 
Exact mechanism of glucose induced ERK5 alteration is still not known, however it is 
possible that glucose induced oxidative stress is a key player in ERK5 change. 
Growth factors such as epidermal growth factor (EGF) and nerve growth factor (NGF) 
activate ERK5 (Kamakura et al., 1999;Kato et al., 1998). Hence several additional 
mechanisms may potentially regulate glucose induced ERK5 alteration. We however, 
understand some of the limitations of this study as the in vitro experiments were 
performed in the microvascular cells of non-retinal origin. We tried to address some 
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of these problems with simultaneous experiments at levels of complexities, i.e., retinal 
tissues. However, additional future studies are needed in various cell types to further 
characterize these changes. 
 
In summary, this is the first study to show that ERK5 may potentially regulate 
VEGF upon high glucose treatment in the ECs and in the retina of diabetic rats. 
Although this study was done in the context of diabetic retinopathy, it is possible that 
these mechanisms are important in other diabetic complications involving VEGF 
signaling. ERK5 may also provide an attractive target for drug development in DR 
and other diabetic vascular complications. 
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CHAPTER 4: ERK5 suppresses glucose-induced extracellular matrix production 
via inhibiting TGFβ1 signaling in endothelial cells 
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4.1 INTRODUCTION 
 
Extracellular matrix (ECM) protein overproduction is a characteristic feature of 
diabetic vascular complications. Studies in our lab and others have shown that the 
synthesis of fibronectin (FN), one of the abundant ECM proteins is upregulated in 
diabetes as well as in endothelial cells (ECs) treated with high level of glucose (Chen et 
al., 2003a;Chen et al., 2003b;Kaur et al., 2006;Roy et al., 1996). FN, a glycoprotein of 
250 KD, is an important component of the extracellular matrix. FN regulates various 
functions of vascular ECs, such as adhesion, migration, growth and proliferation (Madri 
et al., 1988;Pankov and Yamada, 2002;von der et al., 1992). FN and its splice variants 
also play roles in new vessel formation, by providing outside-in signaling between the 
matrix and the ECs (Astrof and Hynes, 2009;Khan et al., 2005). 
 
Increased FN expression has been demonstrated in several tissues in diabetes. We 
and others have shown increased FN mRNA and protein expression in the retina of 
diabetic animals (Kaur et al., 2006;Roy et al., 1996). We have demonstrated that 
increased endothelin-1 (ET-1) mediates glucose-induced FN synthesis via activation of 
nuclear factor-κB (NF-κB) and activating protein-1 (AP-1) and transcriptional coactivator 
p300 (Chen et al., 2003a;Chen et al., 2003b;Chen et al., 2010;Kaur et al., 2006). We have 
further shown that ET-1 and Transforming growth factor beta 1 (TGFβ1) are major 
regulators of FN production (Khan et al., 2006). Multiple signaling pathways have been 
found to involve such change in the endothelial cells. Several studies have shown that 
glucose-induced protein kinase C (PKC) and mitogen activated protein kinase (MAPK) 
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activation mediate FN mRNA and protein expression in the ECs (Xin et al., 2004;Xin et 
al., 2005). ERK5 is a new member of MAPK family (Lee et al., 1995;Zhou et al., 1995). 
It remains unknown whether ERK5 regulates FN overproduction in diabetic angiopathy. 
 
ERK5, also known as big MAPK1 (BMK1), is the most recently identified 
member of MAPK family (Lee et al., 1995;Zhou et al., 1995). ERK5 shares high 
homology in the N-terminal kinase domain with ERK1/2, but has a unique long C-
terminal which has a transcriptional activation domain (Lee et al., 1995;Zhou et al., 1995). 
MAPK/ERK kinase 5 (MEK5) is the specific MAPK kinase for ERK5 activation through 
the phosphorylation of the TEY activation motif in N-terminal (English et al., 1995;Lee 
et al., 1995;Zhou et al., 1995).  It has been shown that ECs express high levels of ERK5 
(Yan et al., 1999). Studies on ERK5 knockout mice have shown that the ERK5 pathway 
is critical for endothelial function and for maintaining blood vessel integrity (Hayashi et 
al., 2004). Our recent studies have demonstrated that ERK5 negatively regulates ET-1 
and vascular endothelial growth factor (VEGF) expression in diabetic vascular 
complications (Wu et al., 2010a;Wu et al., 2010b). FN interacts with ET-1 and VEGF in 
the pathogenesis of chronic diabetic complications (Astrof and Hynes, 2009;Khan et al., 
2005). Thus, it is possible that FN is also regulated by ERK5 signaling.  Moreover, ERK5 
can be activated by neurotrophins in neuronal cells and other cell types (Graiani et al., 
2004;Kamakura et al., 1999;Krabbe et al., 2007;Obara et al., 2009). Whether 
neurotrophins regulate ERK5 signaling in the ECs in hyperglycemia remain to be 
explored. In this study, we investigated whether ERK5 plays any role in glucose-induced 
FN overproduction and the mechanisms of such regulation. We used microvascular ECs, 
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as microvessels are a major target of glucose induced angiopathy. We further expanded 
the investigation to study whether such changes are important in the retina of diabetic 
animals. 
  
4.2 MATERIALS AND METHODS 
 
4.2.1 Cell culture 
 
A dermal-derived human microvascular endothelial cells (HMVECs) were 
obtained from Lonza (Walkersville, MD). HMVECs were grown in endothelial cell basal 
medium 2 (EBM-2, Lonza, Walkersville, MD) containing human epidermal growth factor 
(hEGF), 1‰; Hydrocortisone, 0.4‰; gentamycin, 1‰; fetal bovine serum (FBS), 10%; 
VEGF, 1‰; human basic fibroblast growth factor, 4‰; long R3 insulin-like growth factor, 
1‰; Ascorbic Acid, 1‰. In EBM2, the glucose concentration was 5 mmol/L. Cells at 
80% confluence were growth arrested by incubation in serum-free medium overnight 
prior to incubation with high glucose (25mmol/L D-glucose, Sigma-Aldrich, Oakville, 
Ontario) or osmotic control (L-glucose, Sigma-Aldrich) of the same concentration. To 
determine the effects of NGF on ERK5 activation, a dose-dependent (10 and 100 ng/ml) 
study of recombinant human NGF (R&D Systems, Minneapolis, MN) was performed. 
Control cells were cultured with vehicle (sterile PBS containing 0.1%BSA). 100 ng/ml 
NGF was shown to be the optimal dose. Cells were seeded in 6-well plates, cultured 
overnight and then treated with or without NGF for 48 hours. Samples were collected for 
protein and RNA extractions. 
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4.2.2 Viral gene transfer  
 
ERK5 is activated through the phosphorylation of TEY motif by MEK5. 
Constitutively active human recombinant MEK5 (CAMEK5) adenovirus and dominant 
negative human recombinant MEK5 (DNMEK5) adenovirus (Cell Biolabs, San Diego, 
CA) were applied to upregulate or downregulate ERK5 signaling respectively. The dual 
phosphorylation site S311/S315 in the CAMEK5 adenovirus has been changed to 
D311/D315, a constitutively active form of human MEK5 sequence. DNMEK5 contains 
dominant negative form of human MEK5 sequence which can not be phosphorylated, 
because the dual phosphorylation site S311/S315 has been changed to A311/A315. 
HMVECs were seeded in 6-well plate, cultured overnight and infected with adenovirus 
for 48 hours as described before (Wu et al., 2010a). A non-specific GFP adenovirus (Cell 
Biolabs, San Diego, CA) with the same multiplicity of infection was used as a negative 
control. Transduction efficacy was measured by western blot analysis.  
 
4.2.3 Transfection of siRNA 
 
The ERK5 siRNA (ON-TARGETplus siRNA) was purchased from Dharmacon 
(Lafayette, CO). A non-targeting siRNA (siGENOME Non-Targeting Pool; Dharmacon 
Inc. Lafayette, CO) was used as a negative control. The ECs were transiently transfected 
with 100 nmol/L of control RNA or ERK5 siRNA using siRNA transfection reagent 
(DharmaFECT 4; Dharmacon Inc. Lafayette, CO) following protocols provided by the 
manufacturer as described before (Zuo et al., 2006). The cells were harvested 48 hours 
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after siRNA transfection. siRNA knock-down efficiency was measured by real time RT-
PCR and western blot. 
 
4.2.4 RNA isolation and cDNA synthesis 
 
Total RNA from ECs and rat retinal tissues was isolated using TRIzol™ reagent 
(Invitrogen, Burlington, ON) as previously described (Chen et al., 2003a). RNA was 
quantified by measuring ultraviolet absorbance at 260 nm. cDNA was synthesized using 
2-4 µg total RNA using High Capacity cDNA Reverse Transcription Kit (Applied 
Biosystem, Foster City, CA). The resulting cDNA products were stored at -20°C. 
 
4.2.5 Real time RT-PCR 
 
Real time RT-PCR was performed using the LightCycler (Roche Diagnostics 
Canada, Laval, PQ) as described before (Khan et al., 2004). For a final reaction volume 
of 20 µl, the following reagents were added: 10 µL SYBR Advantage qPCR Premix 
(Clontech, Mountain View, CA), 1µL of each forward and reverse 10 µmol/L primers 
(Table 4.1), 7µL H2O, and 1µL cDNA template. To optimize the amplification of the 
genes, melting curve analysis (MCA) was used to differentiate melting temperature (Tm) 
of specific products from that of primer-dimers. Serially diluted standard template was 
used to construct a standard curve to quantify mRNA levels. The data were normalized to 
housekeeping gene 18S ribosomal RNA or β-actin to account for differences in reverse 
transcription efficiencies and the amount of template in the reaction mixtures.  
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Table 4.1 Oligonucleotide sequences for real time RT-PCR 
Gene Sequence 5’3’ 
ERK5(human) CTGGCTGTCCAGATGTGAA 
ATGGCACCATCTTTCTTTGG 
FN(human and 
rat) 
GATAAATCAACAGTGGGAGC 
CCCAGATCATGGAGTCTTTA 
TGFβ1(human) GCCCACTGCTCCTGTGACA 
CGGTAGTGAACCCGTTGATGT 
NGF(human) GGGTGCCGGGGCATTGACTC 
GAGCGTGTCGGCAGGTCAGG 
BDNF(human) GCGCCACTCTGACCCTGCC 
TCCCGCCCGACATGTCCACT 
NTRK1(human) GGGAGGGCGCCTTTGGGAAG 
ACGCCGAAGAAGCGCACGAT 
NTRK2(human) GGCTGGCACTGGCTGCTAGG 
ACGTGGGACAGGCGAAAGCG 
β-actin (human) CCTCTATGCCAACACAGTGC 
CATCGTACTCCTGCTTGCTG 
18S(human and 
rat) 
GTAACCCGTTGAACCCCATT 
CCATCCAACGGTAGTAGCG 
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4.2.6 Protein extraction 
 
HMVECs were cultured in 25 cm2 tissue culture flasks. Subconfluent cells were 
growth arrested by incubation in serum-free medium overnight prior to stimulation. After 
stimulation, the cells were treated with 0.2 ml of lysis buffer including 25 mmol/L 
Tris·HCl, pH7.5, 150 mmol/L NaCl, 5 mmol/L MgCl2, 1% NP-40, 1 mmol/L DTT,  5% 
glycerol, protease inhibitor (complete Mini tablet, Roche) and phosphatase inhibitor 
cocktail 1 and 2 (Sigma-Aldrich, Saint Louis, MO). Cells were scraped off the flask and 
the samples of protein extract were sonicated on ice with Kontes micro-ultrasonic cell 
disrupter (Kontes, Vineland, NJ). Then, the samples were centrifuged at 15,000g at 4 ºC 
for 15 minutes. Supernatants were stored at -70ºC. Protein concentrations were 
determined by bicinchoninic acid (BCA) protein assay kit (Pierce, Rockford, IL).     
 
4.2.7 Western blot analysis 
 
Protein extract (30 µg) was boiled for 5 minutes and resolved by 10% sodium 
dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). The protein extracts in 
the gels were then transferred to a polyvinyl difluoride (PVDF) membrane (Bio-Rad, 
Hercules, CA). The membrane was blocked for 30 minutes at room temperature with 5% 
BSA in PBS-T. The blots were incubated overnight at 4◦C with rabbit phospho-ERK5, 
rabbit ERK5, rabbit phospho-Smad2, mouse Smad2, rabbit Smad4 antibody (1:1000; Cell 
Signaling Technology, MA), or mouse β-actin antibody (1:400, Santa Cruz Biotechnology, 
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Santa Cruz, CA), followed by incubation with horseradish peroxidase conjugated anti-
rabbit antibody (1:10000, Upstate Biotechnology, Charlottesville, VA) or anti-mouse 
antibody (1:10000, Vector Laboratories, Burlingame, CA) for 1 hour at room temperature 
as described before (Wu et al., 2010a). Visualization of immunoreactive bands were 
performed using an ECL plus chemiluminescence detection kit (Amersham Pharmacia 
Biotechnology, Buckinghamshire, UK).  Blots were quantified by densitometry using 
MochaTM software (SPSS, Chicago, IL).  
 
4.2.8 Enzyme-linked immunosorbent assay (ELISA) for FN 
 
FN is a secreted protein; its measurement in the cell culture media gives accurate 
assessment of its protein level as described by our lab and others (Majumdar et al., 
2009;Weigert et al., 2003). To examine the amount of FN present in the medium during 
cell culture, culture media were collected after high glucose treatment, CAMEK5 and 
DNMEK5 infection, as well as siERK5 transfection and stored at -70ºC.  FN in cell 
culture media was measured using a human FN ELISA kit (Millipore Upstate, Temecula, 
CA, USA) with a sensitivity of 10-20 ng/ml, according to the manufacturer’s instructions. 
The developed color was measured at 450 nm wavelength with the Bio-Rad micro-plate 
reader (Bio-Rad Laboratories, Hercules, CA). The FN value in each sample medium was 
calculated according to a FN standard curve constructed using FN standards provided by 
the kit. Data were expressed in ng/ml. 
 
 149
4.2.9 Animal experiments 
 
All procedures were approved by the University of Western Ontario Council on 
Animal Care Committee. Age-matched male Sprague-Dawley rats were provided by 
Charles River (Wilmington, MA). Diabetes was induced by a single intravenous injection 
of streptozotocin (65 mg/kg, in citrate buffer, pH 5.6). Controls rats were given equal 
volume of citrate buffer (Kaur et al., 2006). The animals were fed standard laboratory 
chow and monitored for glucosuria and ketonuria (Uriscan Gluketo; Yeong Dong, Seoul, 
South Korea). They were sacrificed after 1 month of diabetes. The retinas were separated 
as describe before (Wu et al., 2010a;Wu et al., 2010b) and stored at -70°C.  
 
 
4.2.10 Statistical analysis 
 
Data were presented as the mean ± standard error of mean. Statistical significance 
of difference between groups was tested using Student’s t test or one way analysis of 
variance (ANOVA) followed by LSD post-hoc analysis. Two-way ANOVA was used to 
examine whether adenovirus transduction and HG treatment have interaction on FN 
synthesis. P value less than 0.05 was considered to be significant.  
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4.3 RESULTS 
 
4.3.1 Glucose-induced FN production was regulated by ERK5  
 
A time course study of high glucose (25mmol/L) treatment was performed in 
human microvascular ECs to establish glucose-induced FN alteration. High glucose 
(25mmol/L) treatment significant stimulated FN mRNA and protein production after 24, 
48 and 72 hour treatment (Figure 4.1A-B). On the contrary prolonged glucose treatment 
resulted in initial increase followed by decreased ERK5 signaling (Figure 4.1C) in 
keeping with our previous studies (Wu et al., 2010a;Wu et al., 2010b). Similarly, 
increased FN mRNA expression was observed in retinal tissues of diabetic rats (Figure 
4.1D). Note that FN expression was also significantly increased in control groups (Figure 
4.1B). This may represent changes due to aging and/or an artificial effect caused by 
serum starving. 
 
To study the regulation of ERK5 on FN, gain of function experiments were 
performed. MEK5 specifically activates ERK5 without altering other MAPK. CAMEK5 
recombinant adenovirus transduction up-regulated ERK5 activity through the 
phosphorylation of the TEY activation motif by constitutively activating MEK5, as 
demonstrated by increased phophorylated ERK5 in Western Blot (Figure 4.2A). ERK5 
mRNA was also increased by CAMEK5 transduction (Figure 4.2B). ELISA and real time 
RT-PCR results showed that FN protein and mRNA expression were significantly 
reduced by CAMEK5 transduction under basal (5mmol/L) glucose (Figure 4.2C and 2D). 
 151
High glucose (25mmol/L) stimulated FN production to a less extend after CAMEK5 
transduction comparing with that in GFP control group (Figure 4.2D). Two-way ANOVA 
showed that CAMEK5 transduction interacted with HG treatment in upregulating FN 
production, indicating that CAMEK5 inhibits glucose-induced FN. 
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Figure 4.1 FN expression was increased after high glucose treatment in HMVECs as 
well as in retinal tissues of diabetic rats.  
HMVECs were treated with low glucose (LG, D-glucose, 5mmol/L) or high glucose (HG, 
D-glucose, 25mmol/L) (OC=osmotic control, L-glucose, 25mmol/L) for 24, 48 and 72 
hours.  A) Real-time PCR showed increased FN mRNA expression after 24, 48 and 72 
hours of glucose treatment. B) FN ELISA showed that secreted FN expression was 
elevated after 24, 48 and 72 hours glucose treatment. C) ERK5 mRNA was transiently 
increased after 24 hours glucose treatment, and then decreased after 48 and 72 hours. D)  
FN mRNA expression was significantly higher in retinal tissues of diabetic rats compared 
with normal control. [For A and C, mRNAs are expressed as a ratio to β–actin, 
normalized to 24hLG, *: significantly difference from LG of the same time point, 
n=3/group. For B n=6/group. For D, mRNAs are expressed as a ratio to 18S, normalized 
to control, n=5, * = significantly different from controls]  
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Figure 4.2 ERK5 overexpression by CAMEK5 inhibited basal and high glucose-
induced FN expression in HMVECs. 
HMVECs were transduced with CAMEK5 in normal glucose (5mmol/L) and high 
glucose (25mmol/L) conditions. A) Western blot analysis showed that phsphorylated 
ERK5 (pERK5) was increased in HMVECs transducted with CAMEK5 in comparison 
with GFP control. B) Real time RT-PCR demonstrated increased ERK5 transcripts 
following CAMEK5 transduction. C-D) CAMEK5 transduction significantly inhibited 
FN in protein (C)  and mRNA levels (D) under basal and high glucose conditions, 
measured by ELISA (C) and real time RT-PCR (D) respectively. Two-way ANOVA was 
used to examine the effect of CAMEK5 transduction and glucose treatment respectively, 
and the possible interaction between CAMEK5 transduction and glucose treatment. 
[mRNA were expressed as a ratio to β-actin, normalized to controls, * = significant 
difference from LG, # = significant difference from GFP, † = significant interaction 
between CAMEK5 and HG treatment, n=6/group. ]   
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4.3.2 Inhibition of ERK5 caused FN upregulation  
 
To further characterize regulation of FN production by ERK5, loss of function 
studies were performed using ERK5 siRNA (siERK5) and dominant negative MEK5 
(DNMEK5). siERK5 knocked down ERK5 gene expression and resulted in 70% 
reduction of ERK5 mRNA (Figure 3.2A). ERK5 protein level indicated the efficiency of 
transfection (Figure 4.3A). In parallel, ELISA demonstrated increased FN production 
following siERK5 transfection (Figure 4.3B), further establishing that ERK5 negatively 
regulates FN synthesis. Moreover, we used another method e.g. DNMEK5 to inhibit 
ERK5 activation. As the dual phosporylation site was changed, neither DNMEK5 nor 
ERK5 can be phosphorylated. Western blot analysis showed reduced pERK5 after 
DNMEK5 transduction (Figure 4.3C). DNMEK5 transduction failed to increase FN 
under basal glucose conditions; however, it significantly enhanced high glucose-induced 
FN overexpression (Figure 4.3D). Two-way ANOVA showed that DNMEK5 interacted 
with HG in stimulating FN synthesis. Similarly, glucose-induced ET-1 and VEGF mRNA 
expression were enhanced following DNMEK5 transduction (Figure App-2). 
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Figure 4.3 ERK5 downregulation by siERK5 and DNMEK5 increased FN levels in 
HMVECs. 
A-B) HMVECs were transfected with ERK5 siRNA (siERK5) and control siRNA 
(ctrlsiRNA). Western blot demonstrated that ERK5 levels were suppressed by siERK5 
(A). ELISA showed that secreted FN was increased after siERK5 transfection (B). C-D) 
DNMEK5 was transduced to endothelial cells to inhibit the phosphorylation of ERK5. C) 
Western blot demonstrated that pERK5 was significantly inhibited by DNMEK5 in 
comparison with GFP control. D) Real time RT-PCR revealed an elevation of glucose-
induced FN levels in DNMEK5 group. Two-way ANOVA was used to examine the effect 
of DNMEK5 transduction and glucose treatment individually, and the possible interaction 
between DNMEK5 transduction and glucose treatment. * =significance from control 
siRNA or GFP+LG, † = significant interaction between DNMEK5 and HG treatment. For 
B, n=6/group, for D, n=3/group. 
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4.3.3 ERK5 regulated FN production through TGFβ1 signaling  
 
It has been well established that high glucose causes upregulation of TGFβ1 
expression in association with Smad2 phosphorylation. To investigate whether TGFβ1 
mediates ERK5 signaling on FN synthesis, we examined TGFβ1 expression in gain and 
loss of function experiments of ERK5. We transduced cells with CAMEK5. Such 
transduction significantly reduced TGFβ1 mRNA expression (Figure 4.4A). On the other 
hand, ERK5 siRNA transfection upregulated TGFβ1 mRNA expression (Figure 4.4B). As 
Smad family mediates TGFβ1 signaling, we examined pSmad2, total Smad2, and Smad4 
using western blot. pSmad2 was greatly diminished by CAMEK5 transduction, while 
total Smad2 and Smad4 were not significantly altered (Figure 4.4C). Two-way ANOVA 
demonstrated that both CAMEK5 transduction and glucose treatment had an effect on 
TGFβ1 signaling. In addition, CAMEK5 transduction interacted with glucose treatment 
in regulating pSmad2, in other words, glucose-induced pSmad2 expression was decreased 
after CAMEK5 transduction (Figure 4.4D). Taken together, these results suggest that 
TGFβ1 signaling may mediate the regulation of ERK5 on FN. 
It has been demonstrated that hyperglycemia-induced augmented ET-1 production 
causes increased FN deposition (Chen et al., 2002;Chen et al., 2003a;Evans et al., 2000). 
Hence, we investigated whether ET-1 mediates the effect of ERK5 on FN. Previous study 
found that ERK5 suppressed ET-1 expression (Wu et al., 2010a). However, exogenous 
human ET-1 peptide failed to rescue the inhibition of CAMEK5 on FN synthesis (data 
not shown), excluding the possibility that ET-1 participates in the regulation of ERK5 on 
FN.  
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Figure 4.4 TGFβ1 signaling mediates the effect of ERK5 on FN in HMVECs. 
A) Real time RT-PCR showed diminished TGFβ1 mRNA after CAMEK5 transduction 
compared with GFP control. B) Real-time PCR showed ERK5 siRNA transfection 
increased TGFβ1 mRNA expression. [mRNA are expressed as a ratio to β-actin, 
normalized to GFP control. *: significant difference from GFP control or control siRNA. 
n=6/group] C) Representative western blot showed diminished pSmad2 after CAMEK5 
transduction in both low glucose (LG, 5mmol/L) and high glucose (HG, 25mmol/L) 
conditions. D) Densitometric quantification of pSmad2 expression. [Data are expressed 
as a ratio to total Smad2, Two-way ANOVA was used to examine the effect of CAMEK5 
transduction and glucose treatment respectively, and the possible interaction between 
CAMEK5 transduction and glucose treatment. * = significant difference from LG in GFP 
group, # = significant difference from GFP, † = significant interaction between CAMEK5 
and HG treatment, n=3/group.]  
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4.3.4 NGF regulated ERK5 signaling under high glucose conditions. 
 
Neurotrophins, such as nerve growth factor (NGF) and brain-derived neurotrophic 
factor (BDNF), are known to regulate ERK5 in the neuronal cells (Cavanaugh, 
2004;Watson et al., 2001).  ECs also express neurotrophins (Graiani et al., 2004;Kermani 
and Hempstead, 2007). To investigate if neurotrophins are upstream regulators of ERK5, 
we examined expressions of NGF, BDNF and their receptors in ECs using real time RT-
PCR. We observed an initial increase and then a decrease of neurotrophins and their 
receptors following 25mmol/L glucose treatment (Figure 4.5 A-D). This finding 
paralleled the alteration of ERK5 (Figure 4.1C) and as described in previous publications 
(Wu et al., 2010a;Wu et al., 2010b). To further characterize the role of NGF, ECs were 
incubated with human recombinant NGF. Result showed that exogenous NGF induced 
ERK5 mRNA production (Figure 4.6B) and ERK5 phosphorylation (Figure 4.6A), which 
was further augmented by 24h glucose treatment (Figure 4.6A).  
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Figure 4.5 Alterations of neurotrophins and their receptors parallel ERK5 after high 
glucose treatment in HMVECs.  
Microvascular endothelial cells were treated with 25mmol/L glucose (HG) for up to 48 
hours. A-B) Real-time PCR showed that NGF (A) and BDNF (B) mRNA expression were 
increased initially (after 24 hours) and then decreased (after 48 hours). C-D) Similar 
results were observed in receptors of neurotrophins NTRK1 (C) and NTRK2 (D). 
[mRNAs are expressed as a ratio to β–actin, normalized to 24hNG, *: significant 
difference from LG of the same time point, n=3/group. LG=5mmol/L glucose, 
HG=25mmol/L glucose.] 
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Figure 4.6 NGF treatment increased ERK5 phosphorylation and ERK5 expression 
in HMVECs  
A) Western blot showed that exogenous NGF treatment led to significant increase of 
pERK5. Total ERK5 was also elevated but was less significant than pERK5. Twenty four 
hour glucose treatment further enhanced NGF induced ERK5 phosphorylation. B) Real 
time RT-PCR demonstrated increased ERK5 mRNA after NGF treatment. [mRNAs are 
expressed as a ratio to β–actin, normalized to control, *: significant difference from 
control, n=3/group.] 
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4.4 DISCUSSION 
 
FN deposition is an important characteristic of endothelial injury in chronic 
diabetic complications (Chen et al., 2003a;Chen et al., 2003b;Kaur et al., 2006;Roy et al., 
1996). Several factors and signaling pathways have been found to be associated with FN 
overproduction in diabetes and in high glucose (Chen et al., 2003a;Chen et al., 
2003b;Kaur et al., 2006;Lan et al., 2011;Peng et al., 2008;Xin et al., 2004;Xin et al., 
2005). In this study, we investigated the role of ERK5 signaling in FN synthesis and 
demonstrated that ERK5 negatively regulates basal and glucose-induced increased FN 
expression in ECs. FN accumulation is an important feature of DR and other chronic 
vascular diabetic complications. We also observed increased FN expression (Figure 4.1) 
and decreased ERK5 activation (Figure 3.5 and Figure 2.6) in retinal tissues of diabetic 
rats, indicating that attenuated ERK5 signaling may be of importance in the pathogenesis 
DR. 
 
This study demonstrated that ERK5 inhibits extracellular matrix deposition in 
ECs. However, ERK5 may play a different role in mesangial cells in diabetes. It has been 
reported that ERK5 activation stimulates mesangial cell proliferation and extracellular 
matrix (collagen I) accumulation (Dorado et al., 2008;Suzaki et al., 2004). Similarly, 
ERK5 increases mesangial cell viability and collagen matrix accumulation in 
glomerulonephritis (Urushihara et al., 2010). The differences between mesangial cells 
and ECs indicate that ERK5 signaling may regulate FN production in a cell type-specific 
manner. It has been found that effects of ERK5 in cell migration are also cell type-
 168
specific. Constitutively activation of ERK5 inhibited EC migration, however, no such 
inhibition was observed in murine fibroblasts (Spiering et al., 2009). In accordance with 
Spiering et al’s results, Schramp et al. also demonstrated that ERK5 promotes podosome 
formation and migration in fibroblast (Schramp et al., 2008). Similar to fibroblast, 
keratinocyte migration was also blocked by ERK5 silencing in cutaneous wounds 
(Arnoux et al., 2008), whereas EC migration was markedly increased by ERK5 shRNA 
(Spiering et al., 2009). Associated with cell migration, cytoskeleton remodeling regualted 
by ERK5 is also cell type-specific. Keratinocytes transfected with shERK5 showed an 
altered, more compact morphology, along with disruption of desmosome organization 
(Arnoux et al., 2008). In contrast, ERK5 activation in cardiomyocytes by constitutively 
active MEK5 or cytokine leukemia inhibitory factor (LIF) resulted in an elongated 
morphology and sarcomere alteration causing an eccentric cardiac hypertrophy were 
assembled in a serial manner, which led to eccentric cardiac hypertrophy (Nicol et al., 
2001). In ECs, activation of ERK5 signaling by a constitutively active MEK5 resulted in 
increased flattening of cells with fewer protrusions and enhanced number of focal 
contacts (Spiering et al., 2009).  
 
 Interestingly, a recent report showed that ERK5 mediates renal protection from 
renal ischemia reperfusion injury (Kawakami et al., 2012). As demonstrated in our and 
other studies, ERK5 mediated protection may be mediated through its effect in 
endothelial signaling (Woo et al., 2008;Wu et al., 2010a;Wu et al., 2010b). Whether effect 
of ERK5 signaling can produce clinically significant retinal and renal protection in 
diabetes need further investigation. 
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Our study demonstrated that constitutive activation of ERK5 signaling strongly 
inhibited FN production in both basal and high glucose conditions (Figure 4.2). The 
alteration of FN after CAMEK5 transduction was much stronger in comparison with that 
induced by siERK5 or DNMEK5. This may due to the fact that CAMEK5 increases both 
ERK5 phosphorylation (Figure 4.2A) and ERK5 expression (Figure 4.2B). Studies have 
shown that transcriptional activation of ERK5 greatly enhanced the effect of ERK5 
(Morimoto et al., 2007). In contrast, ERK5 siRNA decreases ERK5 gene expression and 
DNMEK5 inhibits the ERK5 phosphorylation activation respectively. Similar 
phenomenon was also observed by others cell migration study of ERK5 (Spiering et al., 
2009). FN plays a major role in cell adhesion and migration (Yamada, 2000). Since 
ERK5 negatively regulates FN, it is possible that ERK5 inhibits migration by suppressing 
FN. 
 
We also explored the possible mediator of the inhibition of ERK5 on FN. It has 
been established that TGFβ1 regulates the expression of FN (Ignotz and Massague, 
1987;Roberts et al., 1988). Glucose induces TGFβ1 in endothelial cells (Morishita et al., 
1997;Pascal et al., 1999). In this study, we found a significant inhibition of TGFβ1 
signaling following CAMEK5 transfection, and an increase of TGFβ1 mRNA after 
siERK5 transfection (Figure 4.4). KLF2 may mediate the inhibition of ERK5 signaling 
on TGFβ1. KLF2 is a downstream target of ERK5 signaling (Parmar et al., 
2006;Sunadome et al., 2011). CAMEK5 adenovirus used in our study increased 
transcription factor KLF2 expression, while ERK5 siRNA reduced KLF2, as described in 
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previous publication (Wu et al., 2010a;Wu et al., 2010b). It has been shown that KLF2 
inhibits TGFβ1 signaling via upregulating Smad7, therefore suppressing phosphorylated 
Smad2, which results in decreased transcriptional activity (Boon et al., 2007). Our study 
also demonstrated diminished pSmad2 by ERK5 upregulation, indicating that TGFβ1 
signaling mediates inhibition of ERK5 on FN. It is to be noted that Smad7 promotor 
activity is induced by TGFβ1 and Smad7 precipitates in a negative feedback to control 
TGFβ1 signaling (Nakao et al., 1997). However, the KLF2-mediated induction of Smad7 
has been demonstrated to be independent of TGFβ1 stimulation (Boon et al., 2007). 
Further exploration of the role of Smad7 in ERK5 activation is needed.  
 
Neurotrophins, such as NGF and BDNF, are growth factors that promote survival 
and function of neurons (Allen and Dawbarn, 2006). ERK5 is activated by neurotrophins 
in neuronal cells and mediates a survival response (Cavanaugh, 2004;Watson et al., 2001). 
Neurotrophins can also activate ERK5 in other cell types (Kamakura et al., 1999;Obara et 
al., 2009). In ECs, ERK5 has been demonstrated a mediator of neurotrophin’s effect 
(Kermani and Hempstead, 2007). It has been shown that neurotrophins expression is 
diminished in diabetes (Graiani et al., 2004;Krabbe et al., 2007). We previously observed 
decreased ERK5 signaling after prolonged glucose treatment (Wu et al., 2010a;Wu et al., 
2010b). It is possible that neurotrophins are involved in the regulation of glucose-induced 
ERK5 alteration. We demonstrated that alteration of NGF, BDNF and their receptors 
NTRK1, NTRK2 paralled ERK5 in endothelial cells treated with glucose (Figure 4.5). 
Further, human recombinant NGF treatment stimulated both ERK5 phosphorylation and 
transcription in normal and in high glucose (Figure 4.6), indicating its role in this process. 
However, ERK1/2 was also activated by exogenous NGF treatment in ECs (data not 
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shown). NGF activates both ERK5 and ERK1/2 in many cell types (Cavanaugh et al., 
2001;Kamakura et al., 1999;Obara et al., 2009). Further study need to be done to explore 
the effect of differential activation of ERK1/2 and ERK5.   
 
Gain and loss of function studies demonstrated that ERK5 negatively regulates 
FN production. However, there is a discrepancy between FN expression and ERK5 
activation in the time course study of glucose treatment. After 24h glucose treatment 
ERK5 was still activate at this time point (Wu et al., 2010a;Wu et al., 2010b), however, 
FN production was already elevated comparing with control group (Figure 4.1). It seems 
that even if ERK5 is activated by glucose, it can not completely prevent endothelial 
injury and FN accumulation.  ERK5 is not the only pathway that regulates FN production 
in high glucose condition, but it is the only protective signalling that can inhibit FN 
synthesis. Other signalings such as TGFβ1, ERK1/2, Akt were found to modulate FN in 
high glucose (Pascal et al., 1999;Xin et al., 2004;Xin et al., 2005). The total effect of FN 
inducing pathways may outweigh the effect of ERK5. Another possibility is ERK5 
SUMOylation. Woo and Shishido’s research has found that AGE and H2O2, induced by 
high glucose, promote ERK5 SUMOylation and inhibit transcriptional activity of ERK5 
(Shishido et al., 2008;Woo et al., 2008). That is to say, even ERK5 is phosphorily 
activated, its transcription activity is reduced in high glucose. Thirdly, recent studies 
demonstrated phosphorylation phosphorylation of these atypical sites of ERK5 molecule, 
which has been shown to inhibit ERK5 function. Inhibitory phosphorylation of ERK5 is 
observed after PKCζ activation induced by TNFα treatment (Nigro et al., 2010). Although, 
glucose is not an established inducer of PKCζ activation, it remains unknown whether 
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high glucose can also activate atypical inhibitory phosphorylation of ERK5.      
 
In summary, this study demonstrated a novel pathway that regulates glucose 
induced FN production. The deposition of FN is involved in the pathogenesis of diabetic 
complications. The inhibitory effect of ERK5 on FN shed a light on developing a new 
adjuvant treatment target for diabetic vascular complications. 
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CHAPTER 5:  GENERAL DISCUSSION, CONCLUSION AND FUTURE 
DIRECTIONS 
 
5.1 GENERAL DISCUSSION AND CONCLUSION 
 
Our study focused on understanding the mechanisms underlying DR. Specifically, 
we have studied the role of ERK5, using cultured vascular ECs and animal model of 
diabetic complications. This study showed that ERK5 is negative regulator of multiple 
vasoactive factors, namely, ET-1, VEGF and ECM protein FN. Alteration of these three 
factors are characteristic features of several diabetic complications including DR. We 
have also studied some of the possible upstream and downstream mechanisms of ERK5 
regulation. 
 
We and others have implicated a role of ET-1 is in the pathogenesis of DR (Khan 
and Chakrabarti, 2003). ET-1 is present in retina, and its expression is increased in 
diabetes (Chakrabarti and Sima, 1997;Chakrabarti et al., 1998). Blockade ET increases 
retinal blood flow and prevents DR (Takagi et al., 1996;Shaw et al., 2006). In the first 
part of our study (chapter 2), we investigated the role of glucose-induced ERK5 signaling 
in mediating ET-1 expression (Wu et al., 2010a) (Figure 5.1).  Decrease ERK5 activation 
and increased ET-1 expression were observed in ECs treated with high glucose. We also 
observed similar changes in diabetic rats. Activation of ERK5 by CAMEK5 upregulated 
KLF2 and suppressed both basal and glucose-induced ET-1 expression in ECs. In 
contrast, ERK5 siRNA transfection resulted in decreased ERK5, KLF2 and increased ET-
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1 expression (Wu et al., 2010a). These results indicate that decreased ERK5 signaling 
induced by high glucose contributes to elevated ET-1 expression in DR. ET-1 
upregualtion plays a pathological role in DR, targeting ET-1 may be beneficial 
therapeutic approach.  
 
VEGF is a major contributor of retinal neovasculariztion in DR (Pe'er et al., 
1995;Ray et al., 2004). Elevated VEGF mRNA and protein expression has been 
demonstrated in patient with DR (Boulton et al., 1998;Lutty et al., 1996;Malecaze et al., 
1994), in the retina of streptozotocin-induced diabetic rats (Cukiernik et al., 
2004;Hammes et al., 1998), and in glucose exposed in ECs (Chen et al., 2000;Gao et al., 
2008). ERK5 has been shown involved in the regulation of VEGF. VEGF expression is 
upregulated in ERK5 knockout mice (Chen et al., 2000;Gao et al., 2008;Sohn et al., 
2002;Sohn et al., 2005).  Further study in vitro showed that ERK5 repressed VEGF 
expression by negatively regulating hypoxia inducible factor-1α (HIF1α) in bovine lung 
microvascular ECs (Pi et al., 2005). HIF1α is a strong mediator of angiogenesis in 
hypoxia by regulating VEGF (Semenza, 1999;Shweiki et al., 1992). High glucose 
induces a state of pseudo-hypoxia in diabetic complications (Van den Enden et al., 
1995;Williamson et al., 1993). It is therefore possible that decreased ERK5 signaling may 
promote glucose-induced VEGF production and angiogenesis via HIF1α.  The process of 
angiogenesis consists of a series of linked, sequential steps among which EC migration is 
a central step (Mauriz and Gonzalez-Gallego, 2008). A recent study has shown that 
ERK5 regulates EC migration by inhibiting focal contact turnover (Spiering et al., 2009). 
Constitutive activation of ERK5 signaling strongly inhibited EC migration, whereas 
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ERK5 siRNA transfection increases migration (Spiering et al., 2009). Similarly, our 
experiments showed that ERK5 siRNA enhances tube formation and VEGF expression in 
the ECs. Constitutively activation of ERK5 by CAMEK5 reduced both basal and 
glucose-induced VEGF expression (Wu et al., 2010b). In addition, we observed 
decreased ERK5 signaling and increased VEGF expression in the retina of diabetic rats. 
These results indicates that glucose-induced decreased ERK5 activation contributes to 
increased VEGF expression and function in DR (Wu et al., 2010b) (Figure 5.1). 
 
FN is an important component of the extracellular matrix, which plays an 
important role in EC adhesion, migration, growth and proliferation (Madri et al., 
1988;Pankov and Yamada, 2002). FN overproduction is a characteristic feature of DR. 
Studies in our lab and others have shown that the synthesis of FN is upregulated in 
diabetes and in ECs treated with glucose (Chen et al., 2003b;Chen et al., 2003a;Kaur et 
al., 2006;Roy et al., 1996). We have found a significant decrease of FN mRNA and 
protein following CAMEK5 transduction in basal and high glucose conditions. In 
contrast, ERK5 siRNA infection and DNMEK5 transduction lead to an increase of FN 
synthesis   (chapter 4). Moreover, our study has demonstrated that TGFβ1 signaling 
mediates the effect of ERK5 on FN. Furthermore, we have observed that FN expression 
in retinal tissues of diabetic rats is increased while ERK5 activation is decreased (chapter 
4). These data suggested that decreased ERK5 signaling is important in glucose-induced 
FN overproduction and in DR (Figure 5.1). 
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Our study has demonstrated that ERK5 is initially activated by glucose. As 
osmotic stress is an ERK5 activator, L-glucose (25mmol/L) was used as an osmotic 
control. Our results indicate that 25mmol/L L-glucose has no effect on ERK5 activation 
in the endothelial cells.  However, prolonged glucose treatment, simulating sustained 
hyperglycemia, decreases ERK5 activation, and contributes to EC dysfunction, which is 
characterized by increased vasoactive factors and extracellular matrix accumulation. In 
keeping with our data, a previous study showed glucose induced initial ERK5 activation 
in pulmonary artery ECs (Liu et al., 2000). However, detailed mechanism of glucose-
induced alteration of ERK5 was not previously explored. ERK5 is the most recently 
identified member of MAPK family. It is different from other MAPKs because of its 
unique C-terminal, which contains transcriptional activation domain. Transcriptional 
activation can enhance the effect of ERK5 signaling (Morimoto et al., 2007). Hence, we 
examined ERK5 transcription in our study which paralleled its downstream effects. 
Expression of this transcription domain is sufficient to drive MEF2 and regulate MEF2-
dependent gene expression (Kasler et al., 2000). ERK5 also activates signaling through 
traditional phosphorylation (Kato et al., 2000). Studies have shown that due to the 
activated kinase activity, ERK5 undergoes autophosphorylation on its most C-terminal 
region, which is required for the C-terminal-half to enhance the ERK5 activity 
(Morimoto et al., 2007). In this study, we have demonstrated both increased ERK5 
transcription and phosphorylation. These data indicate that both mechanisms may be 
involved in glucose induced upregulation of downstream molecules. 
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This study used CAMEK5 recombinant adenovirus to upregulate ERK5 signaling 
and ERK5 siRNA or DNMEK5 recombinant adenovirus to downregulate ERK5 signaling. 
Results showed that CAMEK5 transfection strongly inhibited ET-1, VEGF and FN 
production in both basal and high glucose condition. However, ERK5 siRNA or 
dominant negative MEK5 increased those factors less prominently. This may due to the 
fact that CAMEK5 increased both ERK5 phosphorylation and ERK5 transcript. In 
contrast, ERK5 siRNA decreased ERK5 transcript and DNMEK5 inhibited the ERK5 
phosphorylation activation respectively. Therefore the efficiency of ERK5 
downregulation by siERK5 and DNMEK5 is lower than the efficiency of ERK5 
upregulation by CAMEK5. Similar phenomenon is also observed in migration study of 
ERK5 (Spiering et al., 2009). Despite the different efficacy, these experiments showed 
that ERK5 signaling regulated ET-1, VEGF and FN in both basal and high glucose 
conditions. In addition, possible interaction of ERK5 signaling and glucose treatment was 
examined using two-way ANOVA. Such analyses confirmed that ERK5 regulate basal 
and glucose-induced VEGF (Figure 3.2 and 3.4E) and FN expression (Figure 4.2D and 
4.3D). Two-way ANOVA further confirmed similar regulation in case of ET-1, only 
when transduced with higher dose of CAMEK5 (Figure 2.5B). 
 
We have further shown in this study, that regulation of ERK5 on ET-1, VEGF and 
FN may occur via MEF2 and KLF2. MEF2 has been shown to be a direct substrate of 
ERK5 (Kato et al., 1997;Kato et al., 2000;Yang et al., 1998).  Activation of the MEF2 by 
the ERK5 is critical for EC survival and proliferation (Kato et al., 1997;Olson, 2004). 
ERK5 drives KLF2 transcription by activating MEF2 (Sohn et al., 2005). KLF2 plays 
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important role in regulating inflammation and angiogenesis and maintaining vascular 
quiescence (Boon and Horrevoets, 2009;Dekker et al., 2006;Senbanerjee et al., 
2004;Sohn et al., 2005;Suzuki et al., 2005). We have observed alteration of MEF2 and 
KLF2 in parallel with that of ERK5 following high glucose treatment. Furthermore, 
CAMEK5 transfection markedly increased MEF2 and KLF2. Whereas, silencing ERK5 
gene significantly decreased MEF2 and KLF2. Although we did not perform direct 
experiments to prove the cause and effect relationship of ERK5 and its downstream 
targets, these results suggest that MEF2 and KLF2 may possibly be mediators of ERK5 
signaling in the regulation of vasoactive factors studied in this project (Figure 5.1).  
 
Microarray expression profiling has shown that KLF2 overexpression inhibits ET-
1 and VEGF, but does not directly regulate FN (Boon et al., 2007). It has been 
established that TGFβ1 regulates the expression of FN (Ignotz and Massague, 
1987;Roberts et al., 1988). High glucose treatment induces TGFβ1 in ECs (Morishita et 
al., 1997;Pascal et al., 1999). We found a significant inhibition of TGFβ1 signaling after 
CAMEK5 transfection, and an increase of TGFβ1 mRNA after siERK5 transfection, 
suggesting that TGFβ1 signaling mediates the effect of ERK5 on FN. Other researchers 
have shown that KLF2 lentivirus transfection inhibits TGFβ1 signaling (Boon et al., 
2007). Thus, it is possible that MEF2-KLF2- TGFβ1 mediates the regulation of ERK5 on 
FN (Figure 5.1).  In addition, we investigated whether ET-1 mediates the effect of ERK5 
on FN. Previous study found that ERK5 suppressed ET-1 expression (Wu et al., 2010a). 
It has also been demonstrated that hyperglycemia-induced augmented ET-1 production 
causes increased FN deposition (Chen et al., 2002;Chen et al., 2003a;Evans et al., 2000). 
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Thus, it is possible that ET-1 mediates the inhibition of ERK5 on FN. However, 
exogenous human ET-1 peptide failed to rescue the inhibition of CAMEK5 on FN 
synthesis (data not shown), excluding the possibility that ET-1 participates in the 
regulation of ERK5 on FN. 
 
We have also investigated upstream regulation of ERK5 signaling in high glucose 
and have found that NGF mediates glucose-induced alteration of ERK5 (Figure 5.1). 
ERK5 mediates the effect of NGF in neuronal cells, ECs as well as other cell types 
(Cavanaugh, 2004;Watson et al., 2001;Kamakura et al., 1999;Obara et al., 2009). 
Moreover, the expression of neurotrophin is diminished in diabetes (Graiani et al., 
2004;Krabbe et al., 2007), which is in keeping with decreased ERK5 activation in retinal 
tissues of diabetic rats and in ECs after prolonged glucose treatment. This notion was 
further supported by the demonstration that recombinant NGF treatment stimulated both 
ERK5 phosphorylation and transcription in basal and high glucose conditions.   
 
In conclusion, this study explored the role of ERK5 on chronic diabetic 
complication through the investigation of ERK5 on key features of endothelial 
dysfunction in diabetes. We have demonstrated that ERK5 plays an important role in 
protecting glucose induced endothelial cell damage by suppressing of ET-1, VEGF and 
FN expression and function. Glucose-induced, neurotophin mediated decreased ERK5 
signaling leads to upregulation of multiple vasoactive factors and ECM proteins possibly 
through MEF2, KLF2 and TGFβ1 (Figure 5.1).  ERK5 is the only signalling that has 
been found to be protective against endothelial injury in high glucose. Furthermore, 
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ERK5 exerts its effects by acting on multiple factors that are involved in regulating 
endothelial function. Hence, ERK5 may be a potential target for prevention and treatment 
of diabetic microangiopathy. 
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Figure 5.1 A diagrammatic representation of the key findings of this study, outlining 
possible role of ERK5 in diabetic retinopathy. 
Long term hyperglycemia decreased activation of ERK5, which lead to upregulation of 
ET-1, VEGF, FN expression and function, subsequently possibly contributing to diabetic 
retinopathy. NGF mediated hyperglycemia-induced ERK5 alteration. ERK5 exerted its 
effect on endothelial cells via MEF2/KLF2 and TGFβ1.  
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5.2  FUTURE DIRECTIONS 
 
This study investigated the role of ERK5 in diabetic vascular complications, 
specifically in DR. However, the majority of the study was performed using dermal-
derived human microvascular endothelial cells (HMVECs) due to the limited availability 
and poor proliferation of human retinal ECs. Some features of dermal-derived ECs may 
be different from ECs from retinal tissues. Therefore, studies in human retinal ECs are 
needed in the future to examine whether the regulation of ERK5 on ET-1, VEGF and FN 
are the similar as dermal-derived human microvascular endothelial cells. 
 
We have demonstrated that upregulation of ERK5 signaling inhibits ET-1, VEGF 
and FN in basal and high glucose conditions, suggesting that a protective effect of ERK5 
signaling on glucose-induced endothelial dysfunction. Additional studies have shown that 
downregulation of ERK5 signaling increased ET-1, VEGF and FN expression, indicating 
that decreased ERK5 is implicated in the pathogenesis of diabetic vascular complications. 
However, majority of the experiments were performed in vitro using ECs. Studies in both 
type1 and type 2 diabetic animal models, are needed in the future to establish such 
pathogenic mechanisms and their effects on DR. Such experiments will provide valuable 
data to examine potential use of this target to prevent DR or other diabetic complications. 
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APPENDIX 1: Supplementary data 1 
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Figure App-1: pERK5 expression within 1 hour glucose treatment 
HMVECs were cultured without or with high level of glucose (25mmol/L) for different 
time point. Western blot showed that either pERK5 or ERK5 were altered within 1 hour 
HG treatment. β-actin was used as a loading control. 
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APPENDIX 2: Supplementary data 2 
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Figure App-2: DNMEK5 transduction enhanced glucose-induced ET-1 and VEGF 
mRNA in HMVECs. 
A) Real time RT-PCR showed that glucose-induced ET-1 mRNA expression was 
increased following DNMEK5 transduction. Two-way ANOVA was applied to examine 
the individual effects of DNMEK5 transduction and HG treatment, as well as the possible 
interaction between these two factors. Statistical analysis demonstrated that HG increased 
ET-1 expression; DNMEK5 did not have significant effect on ET-1 in basal glucose 
(LG). However, DNMEK5 interacted with HG and enhanced glucose-induced ET-1. 
Similar result was found in VEGF (B). [mRNA are expressed as a ratio to β-actin, 
normalized to controls, * : significant difference from LG, † : significant interaction 
between DNMEK5 and HG treatment, n=3/group ]   
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